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ABSTRACT 
Eosinophils are considered key effector cells in the pathogenesis of allergic diseases. 
In particular, eosinophils are activated at sites of inflammation to release cytotoxic 
cationic proteins which are thought to promote disease by inducing tissue damage and 
dysfunction. Indeed, eosinophil degranulation is a key feature of allergic disorders and 
the levels of secreted products often correlates with disease severity. Although mouse 
models of allergic airways disease reproduce several features of human asthma, 
ultrastructural evidence of active granule disassembly in mouse eosinophils has not 
been reported. This apparent absence of eosinophil degranulation has questionned the 
validity to employ this specie to model the contribution of eosinophils to the 
pathogenetics of allergy. In this thesis, it is demonstrated that mouse eosinophils 
release granule proteins by piecemeal degranulation in the allergic lung of mice. 
However, eosinophil degranulation is most prominent in , and primarily 
compartmentalized to, the airways lumen. Accordingly, recruitment and activation of 
eosinophils in the lung correlates with the detection of cell-free eosinophil peroxidase in 
BALF and with the induction of airways hyperreactivity. Furthermore, in vitro 
investigations revealed that higher concentrations of exogenous stimuli appear to be 
required to trigger both adherence and degranulation of mouse eosinophils when 
compared to values reported for studies of human eosinophils suggesting inter-specie 
differences in the threshold of eosinophil activation. Failure of eosinophils to 
degranulate in the allergic lung may reflect the acute nature of the inflammatory 
response in mice or the requirement for higher levels of. stimuli to activate this cell. 
Thus, mouse eosinophils undergo piecemeal degranulation during allergic 
inflammation, and in turn, this process may contribute to pathogenesis. However, the 
degranulation process in the allergic lung of mice is spatially distinct from that observed 
in human disease. 
Since the level of eosinophil activation increased as the cell migrated from the bone 
marrow to the airways lumen, a method which permits the purification of eosinophils 
from the different compartments may permit the identification of key regulators of 
eosinophil activation. A method to purifiy eosinophil populations from the bone marrow, 
blood and BALF of allergic mice was developed using FACS. The basis for the isolation 
method is the high SSC and light polarization properties of eosinophils. Importantly, the 
purified eosinophils (>96°/o) were viable (>95°/o) and responded to stimulation . 
Preliminary investigations highlighted the presence of several differentially expressed 
genes, including cytokines, cytotoxic granule proteins and chemokine and cytokine 
IV 
receptors, between bone marrow and BALF eosinophils. This investigation provides a 
method to purify eosinophils from all compartments and subsequently, characterize the 
phenotypic differences between eosinophil populations. 
In conclusion, mouse models of experimental asthma may provide a tool to further 
elucidate the mechanisms regulating eosinophil activation in vivo. A better 
understanding of mechanisms modulating eosinophil degranulation may provide a 
platform for the development of novel therapeutic agents for the treatment of allergic 
inflammatory diseases. 
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1.1 INTRODUCTION 
Asthma is a chronic inflammatory disease of the lower airways with a disproportionate 
prevalence in industrial and urban regions around the world (Busse and Lemanske, 
2001; Yaztlanbakhsh et al. , 2002). The morbidity and mortality of asthma has 
increased alarmingly over the last two decades highlighting the importance for the 
development of new therapeutic strategies (Maddox and Schwartz, 2002). 
The causes of asthma are complex and multifactorial. Both a genetic predisposition 
and environmental factors are linked to the development of asthma (Maddox and 
Schwartz, 2002). Asthmatics have been divided into two groups based on the stimuli 
responsible for exacerbation of disease. In extrinsic asthma, sensitization to an 
environmental allergen leads to the production of antigen-specific immunoglobulin (lg) 
E and subsequent exposure to the allergen induces clinical manifestations of disease 
(Bochner et al., 1994 ). In a smaller proportion of the population, intrinsic asthma is 
observed whereby patients do not demonstrate elevated serum lgE levels and factors 
such as exercise and aspirin sensitivity initiate the onset of disease (Bochner et al., 
1994). 
The clinical features of asthma are reversible airflow obstruction , airway 
histopathologies, airways hyperreactivity (AHR) to inhaled spasmogens and an 
underlying chronic inflammation of lower airways consisting of lymphocytes, mast cells 
and eosinophils (Bochner et al. , 1994; Busse and Lemanske, 2001; Maddox and 
Schwartz , 2002) . Recently , the inflammatory process has been considered a key factor 
responsible for the pathophysiological changes associated with asthma. Inflammation 
of the lower airways affects airway epithelial shedding , subepithelial fibrosis, 
hypertrophy and hyperplasia of smooth muscle , plasma extravasation and mucus 
hypersecretion (Barnes, 1996b). However, the cellular composition of the pulmonary 
inflammation changes during the course of disease . The spatial and temporal 
regulation of leukocyte populations has led to two distinct periods of disease in atopic 
patients after allergen inhalation . The early-phase response, which occurs in the first 
hour, is orchestrated by mast cells whereas the late-phase response, which arises 
between 3 to 11 hours post-allergen provocation , is mediated by CD4+ T-cells and 
eosinophils (Bochner et al., 1994; Busse and Lemanske, 2001 ). The molecules that 
coordinate the differentiation , recruitment and activation of these leukocyte subsets are 
central to the pathogenesis of asthma. Since eosinophils have been associated with 
disease severity , elucidation of the mechanisms regulating eosinophil activation might 
present investigators with new targets for the treatment of allergic diseases. 
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1.2 CELLULAR AND MOLECULAR MECHANISMS REGULATING 
ALLERGIC AIRWA VS DISEASE 
Clinical studies in conjunction with investigations employing animal models have 
identified ke-y effector cells and molecules regulating the pathogenesis of allergic 
airways disease. In the current paradigm (Fig .1.1 ), professional antigen-presenting 
cells (APC), which include dendritic cells and macrophages, regulate the inflammatory 
process instigated by antigen provocation. At the site of allergen exposure , APCs 
sample the microenvironment and process foreign antigens before migrating to the 
draining lymph nodes where they direct T-cell differentiation towards the T-helper (Th) 
type 2 phenotype, and activation of T- and B-cells (Lambrecht et al., 1998). Th2 
lymphocytes secrete a distinct subset of cytokines including interleukin (IL)-2, IL-4, IL-5 
and IL-13, which cooperate to promote eosinophilic inflammation and AHR (Webb and 
Foster, 1999; Webb et al., 2000). IL-2 and IL-4 coordinate the amplification of the Th2 
T-cell population. IL-2 provides a proliferative signal (Toribio et al. , 1989) while IL-4 
polarizes uncommitted T-cells to the Th2 phenotype (Swain et al., 1990). This local 
Eotaxin 
VLA-4 
VCAM1 
IL-4/ 
IL-13 
~ )~ }-
lgAf~'r 
lgE )~ 
lgG 
IL-2/ _.. 
IL-4 
IL-4/ 
IL-13 
FIGURE 1.1- Cellular and molecular mechanisms regulating the pathogenesis of 
allergic airways disease. Upon allergen provocation , APCs activate Th2 lymphocytes 
which secrete various cytokines, notably IL-4, IL-5 and IL-13. The coordinate activities 
of these cytokines results in the generation of a blood and pulmonary eosinophilia , 
activation of eosinophils and potentially , the induction of AHR. (Adapted from Webb 
and Faster, 1999). 
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effect in combination with T-cell activation will lead to a systemic rise in IL-4, IL-5 and 
IL-13 concentrations which control eosinophil function. IL-5 directs the differentiation of 
eosinophil progenitors and mobilization of mature eosinophils into the bloodstream 
whereas IL-4 and IL-13 are implicated in eosinophil recruitment and activation (Mould 
et al., 1997; Sanderson et al., 1985). The migration of eosinophils to the allergic lung is 
regulated by chemotactic factors, principally members of the eotaxin family (Forssmann 
eta/., 1997; Jose eta!., 1994; Kitaura eta/., 1999; Shinkai eta!., 1999). Both IL-4 and 
IL-13 influence eosinophil movement by modulating the expression of eotaxin and 
adhesion systems within pulmonary tissues (Bochner et al., 1995; Doucet et al., 1998; 
Hirst et al., 2002; Li et al., 1999; Moore et al., 2002; Schleimer et al., 1992; Striz et al., 
1999; Terada et al., 2000; Woltmann et al., 2000). Eosinophils present at sites of 
allergic inflammation, subsequently, potentiate disease processes such as AHR 
through the release of pro-inflammatory mediators (Gundel et al., 1991; Uchida et al., 
1993). This latter process may also be influenced by both IL-4 and IL-13 since these 
cytokines are essential for isotype switching of B-cells (Punnonen et al., 1993) and 
immunoglobulins represent a key stimulus for the activation of eosinophil secretory 
pathways (Abu-Ghazaleh et al., 1989; Kaneko et al., 1995b; Khalife et al., 1986; 
Khalife et al., 1985). Finally, IL-4 and IL-13 can directly affect the induction of AHR and 
mucus hypersecretion without the requirement of additional participants (Grunig et al., 
1998; Venkayya et al., 2002; Wills-Karp et al., 1998; Yang et al., 2001 ). Hence, the 
late-phase response associated with asthma arises through the coordinate actions of 
various cytokines on different leukocyte populations. 
1.3 EOSINOPHILS 
Eosinophils are granulocytes derived from myeloid progenitors resident in the bone 
marrow with a dramatic expansion of the eosinophil population in various disorders 
including parasite infections, atopic disease and cancer (Rothenberg, 1998). 
Eosinophils have a protective role against parasite infestations but a pro-inflammatory 
effect during allergic diseases. Indeed, eosinophils are considered key effector cells in 
the pathogenesis of atopic disorders affecting the airway and gastrointestinal mucosa 
(Hogan et al., 2002; Rothenberg, 1998; Wardlaw et al. , 1995). 
Ultrastructural analyses of human eosinophils have revealed several features (Fig.1.2)-
nuclei are polylobed with partially condensed chromatin , irregular surface projections 
and the presence of various secretory granules (Dvorak, 1994; Dvorak et al., 1993a). 
Based on granule content, three granule types have been identified. Primary granules 
are membrane-bound spherical structures with a homogenous content. These granules 
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A B 
FIGURE 1.2- Electron photomicrographs of an eosinophil and its secondary granules. 
A. Ultrastructural features of eosinophils include irregular surface projections, a 
polylobed nucleus and various secretory granules notably secondary granules. B. The 
secondary granule is a spherical, membrane-bound structure, which can be recognized 
by its electron-dense crystal core surrounded by a matrix. These granules are storage 
sites for the cytotoxic cationic proteins and other mediators such as cytokines and 
chemokines. 
'--------------------------,- , --------------' 
are the primary storage site of Charcot-Leyden crystal protein (Dvorak et al., 1988). 
The secondary granule (or specific granule) is also a membrane-bound spherical 
structure but easily distinguishable from other granules since it consists of an electron-
dense crystalloid core surrounded by a less dense matrix. These granules contain the 
cytotoxic cationic proteins as well as several cytokines and chemokines (Egesten et al., 
2001 ). Other visible structures include the small granules which contain hydrolytic 
enzymes (Egesten et al., 2001) and lipid bodies wh ich consists mainly of arachidonic 
acid and its metabolic products (Bandeira-Melo et al., 2002). 
The role of eosinophils in both parasite clearance and pathogenesis of allergic 
diseases is attributable to the release of pro-inflammatory molecules which include the 
cytotoxic cationic granule proteins, lipid mediators, reactive oxygen species , cytokines 
and chemokines . The effect of these mediators in regulating physiological processes 
has been partially defined and will be briefly summarized . 
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1.3.1 Cytotoxic cationic granule proteins 
Human eosinophils are the primary source of a class of pro-inflammatory molecules 
called the cytotoxic cationic granule proteins , which include major basic proteins (MBP-
1 and -2) , -eosinophil peroxidase (EPO) , eosinophil cationic protein (ECP) and 
eosinophil-derived neurotoxin (EON) . The proteins have been classified into this family 
because they share several properties notably, a high isoelectric point (pl) and 
cytotoxicity towards parasites and mammalian cells. 
1.3.1.1 MBP 
MBP-1 and MBP-2 are small proteins of approximately 15 kDa which are highly basic 
(pl = 10.9) (Wasmoen et al., 1988; Pl ager et al., 1999). However, it has been 
hypothesized that to protect the eosinophil , MBP-1 is translated as a prepropeptide 
whereby the amino terminal sequence targets the protein to the appropriate cellular 
compartment and the propeptide which is highly acidic (pl=3.9) neutralizes· the toxicity 
of MBP-1 (Popken-Harris et al., 1998). The mature MBP-1 product is stored in 
secondary granules where it forms the crystal core (Peters et al., 1986). MBP-2 
displays similar properties to MBP-1 (Macias et al., 2000; Plager et al., 1999). 
However, in the absence of MBP-1, no crystal structure is formed in the secondary 
granules suggesting that MBP-2 alone is incapable of forming this structure (Denzler 
et al., 2000). 
Although MBP-1 has no enzymatic activity , it has been directly implicated in the 
clearance of parasites and pathogenesis of allergic diseases. In vitro experiments have 
demonstrated the potential of MBP-1 to kill parasites and bacteria (Butterworth et al., 
1979; Hamann et al., 1987; Hamann et al. , 1990; Lehrer et al., 1989). Furthermore, the 
cytotoxic nature of MBP-1 is extended to several mammalian cells including airway 
epithelial cells (Ayars et al. , 1989; Frig as et al. , 1980; Hisamatsu et al., 1990). MBP-1 
may also contribute to the pathogenesis of allergic airways disease through the 
induction of AHR. In particular, MBP-1 induces AHR when instilled into the airways of 
guinea pigs and primates by inhibiting M2 muscarinic receptor function which leads to 
an increase in acetylcholine concentration and to a subsequent increase in vagally 
induced bronchoconstriction (Gundel et al., 1991 ; Jacoby et al., 1993; Uchida et al., 
1993). Finally , MBP-1 can affect disease processes through its immunoregulatory 
functions. MBP-1 can activate secretory pathways in platelets , mast cells , basophils , 
neutrophils and eosinophils in a noncytolytic mechanism (Kita et al., 1995; Moy et al., 
1990; O'Donnell et al. , 1983; Rohrbach et al. , 1990; Zheutlin et al., 1984). 
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1.3.1.2 EPO 
EPO is the largest cationic granule protein composed of an 11 kDa and a 57 kDa 
subunit in conjunction with a heme-moeity (Ten et al. , 1989). The products of reactions 
catalyzed by- EPO have been associated with the pathogenesis of asthma and cancer 
as well as host defense against parasite and helminth infections. Although substrates 
are not required for EPO-mediated killing of parasites, H20 2 dramatically enhanced the 
cytotoxicity of EPO (Hamann et al. , 1990; Weiss et al., 1986). 
EPO utilizes halides (B(, er, . r) and pseudohalides (SCN-) , but preferentially bromide 
and thiocyanate, in combination with H20 2 to generate the corresponding hypohalous 
acids (van Dalen and Kettle, 2001 ). This reaction has been implicated in the 
bromination of tyrosine residues found in proteins located in the asthmatic lung (Wu et 
al., 1999a; Wu et al., 2000) and in the pathogenesis of cancer through the production 
of mutagenic bromonucleotides and oxidative damage of deoxyribonucleic acid (DNA) 
(Henderson et al., 2001 a; Henderson et al., 2001 b; Shen et al. , 2001 ). Alternatively, 
the hypohalous acid can combine with superoxide to form the highly reactive hydroxyl 
radical which promotes mutagenesis through nucleotide and DNA modifications (Shen 
et al. , 2000). 
Another mechanism for the oxidation of proteins catalyzed by EPO is through the H20 2 
/N02 pathway which results in the nitration of tyrosyl residues in proteins (Brennan et 
al. , 2002; Wu et al. , 1999b). 3-nitrotyrosine, a marker of protein nitration , is elevated in 
the asthmatic lung (MacPherson et al., 2001 ). Moreover, recent evidence suggests that 
protein nitration is eosinophil- and EPO-dependent (Brennan et al. , 2002; lijima et al. , 
2001 ). Although EPO can modify DNA and proteins by various mechanisms, the 
pathological significance of the products has yet to be determined. 
1.3.1.3 ECP and EDN 
ECP and EON are small basic proteins found in the matrix of secondary granules. ECP 
is also toxic towards helminthes, parasites , bacteria and mammalian cellular targets 
(Ackerman et al., 1985; Hamann et al., 1987; Hamann et al. , 1990; Lehrer et al. , 1989; 
Motojima et al., 1989). Although EON can mediate the killing of parasites , it is less 
potent than the other cationic toxins (Ackerman et al. , 1985; Hamann et al. , 1987; 
Hamann et al., 1990). In contrast to MBP-1 and EPO, both ECP and EON could not 
induce bronchoconstriction in primates (Gundel et al., 1991 ). However, ECP and EON 
have been associated with the pathogenesis of the Gordon phenomenon which is a 
disorder afflicting the nervous system (Fredens et al. , 1982). 
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The distinct roles of ECP and EON in disease processes may be due to their particular 
properties. ECP and EON are members of the ribonuclease (RNase) A superfamily 
(Barker et al: , 1989; Rosenberg et al., 1989a; Rosenberg et al., 1989b) and thus, 
possess RNase activity with EON being 100-fold more active than ECP (Slifman et al., 
1986). Mouse eosinophils express a set of 15 genes named eosinophil-associated 
ribonucleases (mEAR) which are the paralogues of the ECP and EON genes of 
primates (Rosenberg and Domachowske, 2001 ). Eosinophils have been traditionally 
associated with Th2 type immunological responses. However, emerging evidence 
suggests that eosinophils , through the coordinate action of the RNases, may play a 
role in host defense against viral pathogens (Domachowske et al., 1998a; 
Domachowske et al., 1998b; Rosenberg and Domachowske, 2001 ). 
1.3.2 Lipid bodies 
Lipid bodies were identified in human eosinophils by electron microscopy as an 
electron-dense, non-membrane bound, spherical structure within the cytoplasm (Weller 
and Dvorak, 1985). Lipid bodies· are composed of arachidonic acid principally in the 
esterified form (Weller and Dvorak, 1985; Weller et al., 1991 ), enzymes required for the 
metabolism of this lipid (Bozza et al., 1997; Dvorak et al., 1994) and signaling 
molecules (Yu et al., 1998). lmmunolocalization studies have demonstrated the 
presence of the eicosanoid-forming enzymes which include 5-lipoxygenase, 
leukotriene (LT) C4 synthase and · cyclooxygenases (Bozza et al., 1997; Dvorak et al., 
1994). The transmission of extracellular signals for the activation of eicosanoid-forming 
enzymes occurs through phospholipase A2 (PLA2) and MAP kinases including ERK1, 
ERK2 and p38 present in lipid bodies (Yu et al., 1998). Thus, lipid bodies contain all 
the components to behave as a separate entity for the regulation of eicosanoid 
production and release. 
The formation of lipid bodies is a characteristic feature of human eosinophil activation. 
Only a few lipid bodies are found in normal peripheral blood eosinophils whereas 
numerous lipid bodies may be found in activated eosinophils (Bozza et al. , 1996; 
Bozza et al., 1998; Bozza et al., 1997; Weller and Dvorak, 1985). Activation human of 
eosinophils leads not only to increased numbers of lipid bodies but also de nova 
synthesis of metabolic enzymes and arachidonic acid metabolism (Bozza et al., 1996; 
Bozza et al., 1997). The production of lipid mediators and subsequent release at sites 
of inflammation may modulate disease processes underlying asthma. 
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1.3.3 Reactive oxygen and nitrogen species 
Activation of eosinophils results in the production of both reactive oxygen and nitrogen 
species. However, the proteins involved in the generation of these oxidants are distinct. 
NADPH oxidases are composed of seven subunits and spatial regulation of these 
proteins modulates enzymatic activity (Babier, 1999). A complex of five proteins is 
localized in the cytoplasm which translocates to the membrane upon cellular activation 
where it associates with cytochrome b558 to form an active complex (Babier, 1999). 
NADPH oxidases catalyze the reduction of oxygen using NADPH to produce 
superoxide, which is highly reactive and can dismutate to form H20 2 , an important 
substrate of peroxidases (Babier, 1978a; Babier, 1978b). The oxidants kill parasites but 
may also harm the surrounding tissues (Babier, 1978a; Babier, 1978b; Henderson et 
al., 2001 a; Henderson et al., 2001 b; Shen et al., 2001; Shen et al., 2000). 
Reactive nitrogen species are generated by several cell types expressing specific 
isoforms of nitric oxide synthase (NOS). Leukocytes including eosinophils express 
inducible-NOS which converts L-arginine to citrulline and NO in a redox reaction 
(Folkerts et al., 2001 ). The concentration of nitric oxide is increased in the exhaled air 
of asthmatics and current evidence suggests that eosinophils are the primary source 
(Barnes, 1996a; lijima et al., 2001 ). The potential fate of NO is dependent on its 
environment since it can react with several molecules including oxygen and superoxide 
or consumed by enzymes such as EPO (Abu-Scud et al., 2001; Beckman and 
Koppenol, 1996). A principal product of NO chemistry is the nitration of tyrosine 
residues in proteins. Within the asthmatic lung, protein nitration is elevated due to the 
catalytic activity of EPO (Brennan et al., 2002; Duguet et al., 2001 ). Unfortunately, the 
contribution of NO to the pathogenesis of allergic airways disease remains unclear. 
Inhibition of NOS had minor effects on the early and late-phase responses in atopic 
patients (Taylor et al., 1998). However, both in vitro and in vivo experiments suggest 
that NO may regulate the recruitment of inflammatory cells (De Sanctis et al., 1999; 
Thomazzi et al., 2001; Xiong et al., 1999). The spatial and temporal regulation of NO 
might be an important aspect during allergic reactions since different NOS isoforms 
have distinct effects on the pathogenesis of disease. Studies using genetically-modified 
mice have revealed an important role for neuronal isoforms of NOS in modulating AHR 
whereas AHR in inducible-NOS knockout mice was not significantly different to wild-
type (WT) mice although , inflammation was reduced (De Sanctis et al. , 1999). 
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1.3.4 Cytokines and chemokines 
Both human and mouse eosinophils are sources of Th1 and Th2 cytokines including IL-
1 a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-16, IL-18, granulocyte 
macrophage-=-colony stimulating factor (GM-CSF), tumor necrosis factor (TNF)-a, 
transforming growth factor (TGF)-a and TGF-~(Egesten et al., 2001; Mattes et al., 
2002; Schmid-Grendelmeier et al., 2002; Woerly et al., 1999).The proteins have a 
wide-range of regulatory functions which permit eosinophils to exert an influence on the 
development of both humoral and cellular immune responses. Eosinophils also 
express chemokines which may amplify eosinophilic inflammation. In particular, 
eosinophils synthesize eotaxin, regulated upon activation in normal T-cells expressed 
and secreted (RANTES), macrophage inflammatory protein (MIP)-1 a and IL-8 
(Egesten et al., 2001). 
1.4 ROLE OF EOSINOPHILS IN ALLERGIC AIRWAYS DISEASE 
The role of eosinophils in the pathogenesis of allergic airways disease remains 
controversial. Over the past decades, several clinical studies have demonstrated a 
strong correlation between eosinophilic inflammation, exacerbation of disease and 
disease severity (Bradley et al., 1991; Fujimoto et al., 1997; Louis et al., 2000; Reed, 
1994). Importantly, activated eosinophils were present at sites of inflammation, which 
was associated with an extensive release of granule proteins in the lower airways of 
asthmatics (Filley et al., 1982). Eosinophils have also been localized in close proximity 
to nerves and smooth muscle within the allergic lung (Evans et al., 2001 ). The spatial 
regulation of eosinophils (Evans et al., 2001) and the ability of MBP-1 and EPO to 
modulate AHR through the allosteric antagonism of inhibitory M2 muscarinic receptors 
(Jacoby et al., 1993) suggests a pro-inflammatory role for eosinophils in the 
pathogenesis of allergic airways disease. 
Studies employing animal models of allergic airways disease have supported these 
concepts. The kinetics for the development of a pulmonary eosinophilia in response to 
aeroallergen challenge correlates with the onset of AHR (Tomkinson et al., 2001 ). 
Furthermore, depletion of IL-5 results in a dramatic reduction in eosinophil recruitment 
to the allergic lung, which accompanies an improvement in various disease parameters 
(Foster et al., 1996; Hamelmann et al., 1999a). Finally, neutralization of eosinophil by-
products, notably MBP-1, inhibited antigen-induced AHR (Lefort et al., 1996). 
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However, other studies dispute this role of eosinophils in atopic diseases. Certain 
clinical studies have failed to correlate eosinophil numbers and AHR (Crimi et al., 
1998). Moreover, the administration of a humanized I L-5 monoclonal antibody to 
asthmatics improved disease processes marginally although it significantly reduced 
blood and pulmonary eosinophilia (Leckie et al. , 2000) . An IL-5 independent 
mechanism for the induction of AHR, which has been interpreted as an eosinophil-
independent mechanism, has also been described in experimental models of asthma 
(Corry et al. , 1996; Hessel et al., 1997; Hogan et al. , 1998). In addition, eosinophil 
degranulation, a hallmark feature of human asthma, does not occur in the submucosa 
of the allergic lung in mice (Malm-Erjefalt et al., 2001; Stelts et al., 1998). These 
findings have led to the suggestion that eosinophils may not regulate certain disease 
processes such as AHR and mucus hypersecretion in experimental models and thus 
by inference, allergic asthma. 
Clearly, eosinophils possess the potential to play a critical role however, additional 
investigations must be undertaken to determine the precise role of eosinophilic 
inflammation in the pathogenesis of allergic airways disease. 
1.5 MECHANISMS OF HUMAN EOSINOPHIL DEGRANULATION 
Eosinophils are secretory cells which store pro-inflammatory mediators in membrane-
bound cytoplasmic granules. The release of the cytotoxic cationic proteins, termed 
degranulation, into the micro-environment may occur via three mechanisms namely 
exocytosis , piecemeal degranulation and cytolysis (Fig.1.3). Electrophysiological 
measurements of activated eosinophils have provided support for the classical 
exocytosis mechanism (Lindau et al. , 1994; Lindau et al., 1993) whereas electron 
microscopic analysis of eosinophils has revealed the occurrence of piecemeal 
degranulation and cytolysis (Dvorak et al., 1992; Dvorak et al. , 1991; Erjefalt et al. , 
1998; Persson and Erjefalt, 1997). 
1.5.1 Classical exocytosis 
Secretion by exocytosis involves fusion of the membrane enveloping the secondary 
granule with the plasma membrane. This process results in an increase in plasma 
membrane surface area which is directly proportional to a subsequent change in 
plasma membrane capacitance . By t ime-resolved patch-clamp capacitance 
measurements , Nusse and colleagues (Nusse et al. , 1990) demonstrated that 
eosinophils secreted secondary granule contents through an exocytotic mechanism 
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FIGURE 1.3- Mechanisms of human eosinophil degranulation. The release of the 
cytotoxic cationic proteins may occur via classical exocytosis , piecemeal degranulation 
or cytolysis. Classical exocytosis is a secretory process whereby the membrane of the 
secondary granule fuses with the plasma membrane resulting in the release of granule 
contents . In addition to single-fusion events , secondary granules may fuse within the 
cytoplasm before release of the granule contents in a process termed compound 
exocytosis and spatial regulation of the secretory process has led to the observation of 
cumulative fusion whereby successive fusion events occur at the initial fusion pore . 
During piecemeal degranulation , small vesicles bud from the secondary granule 
carrying a subset or complete set of mediators which are transported to the cell surface 
to be secreted. Cytolysis is the release of all cellular contents including secondary 
granules upon the rupture of the plasma membrane. 
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upon guanosine triphosphate (GTP)-y-S stimulation. At low concentrations of the GTP 
analogue, the capacitance of cells increased stepwise in accordance with the 
sequential fusion of individual granules with the plasma membrane (Lindau et al., 1994; 
Lindau et al-:, 1993). Furthermore , the number of fusion events was approximately 
equal to the number of secondary grpnules contained in a resting cell (Lindau et al., 
1993). When the concentration of GTP-y-S was increased, fewer but larger increases 
in capacitance were recorded (Lindau et a/. , 1994; Scepek and Lindau , 1993). This 
feature is characteristic of eosinophils undergoing compound exocytosis whereby 
granules fuse together within the cell before transport to the plasma membrane (Lindau 
et al., 1994; Scepek and Lindau, 1993). Finally, eosinophils may target the granule 
proteins to the appropriate extracellular surfaces through a process called cumulative 
fusion requiring the formation of a degranulation sac (Newman et al., 1996; Scepek 
and Lindau , 1993). A fusion pore is created when the first granule fuses with the 
plasma membrane and directs subsequent fusion events at this site. Although few in 
vivo observations of this mechanism have been reported, eosinophils released granule 
contents by exocytosis in the gut of patients suffering from tissue-invasive bacterial 
infections (Dvorak et al. , 1993b). 
1.5.2 Piecemeal degranulation 
Ultrastructural analysis of human eosinophils revealed the occurrence of piecemeal 
degranulation which is characterized by the gradual emptying of the crystalloid 
containing granules (Dvorak et al., 1992; Dvorak et al. , 1991 ). Upon activation of 
eosinophils , small vesicles bud from the secondary granules carrying a subset or 
complete set of mediators and deliver their contents to the extracellular space by 
exocytosis (Dvorak et al., 1992; Dvorak et al., 1991 ). This mechanism permits the 
secretion of specific granule proteins (Tomassini et al., 1991 ; Torpier et al. , 1988). 
Importantly, the nature of the stimuli determines the identity of the granule proteins 
secreted by the eosinophil (Tomassini et al. , 1991). In contrast to exocytosis , 
piecemeal degranulation has been widely observed in both cultured cells and in 
eosinophils present in inflammed tissues (Dvorak, 1994; Dvorak et al. , 1992; Dvorak et 
al., 1991 ; Erjefalt et al., 1998; Erjefalt et al., 1999). 
1.5.3 Cytolysis 
The presence of cytolytic eosinophils and their by-products have been described in 
various disorders associated with an eosinoph ilia wh ich is consistent with the frequent 
observation that tissues afflicted by high levels of eosinophil degranulation present only 
few intact eosinophils (Wardlaw et al., 1995). Notably , cytolysis is the primary 
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mechanism of degranulation in the skin of patients suffering from hypereosinophilic 
syndrome and bullous pemphigoid (Dvorak, 1994). In these diseases, cytolysis is 
characterized by centralization of granules, chromatolysis within the nuclei and loss of 
plasma membrane integrity (Erjefalt et al., 1998). As a result, the entire cellular 
contents of eosinophils are released into the extracellular matrix and clusters of free 
extracellular granules (Cfegs) are generated. Previously, this mechanism of 
degranulation was regarded as a passive form of granule release induced by cell 
injury. However, emerging evidence suggests that cytolysis may be actively regulated 
by the eosinophil and serve as the ultimate form of eosinophil activation (Erjefalt et al., 
1998; Erjefalt et al. , 1999). 
1.5.4 Eosinophil degranulation in the airways 
Although the release of granule proteins in the airways of asthmatic patients has been 
observed for several decades, the mechanism of eosinophil degranulation has been 
investigated only recently. Ultrastructural analysis of eosinophils present in the airways 
of patients suffering from allergic rhinitis show that the majority of eosinophils released 
granule contents by piecemeal degranulation with a significant proportion of 
eosinophils undergoing cytolysis (Erjefalt et al., 1998; Erjefalt et al. , 1999). Although 
fewer eosinophils were cytolytic, these cells may contribute the greatest proportion 
towards the cytotoxic granule protein concentration within the airways. 
In summary, eosinophils can utilize classical exocytosis, piecemeal degranulation or 
cytolysis to release the contents of secondary granules. However, the extracellular 
stimuli and their intracellular signaling pathways regulating these 3 processes have yet 
to be defined. It will be interesting to determine how the mechanisms of eosinophil 
degranulation are differentially regulated both by the nature of the stimuli and the 
specific intracellular cascades. 
1.6 ACTIVATION OF HUMAN EOSINOPHILS 
The cellular functions of eosinophils are regulated by the activation status of the cell. 
Several changes in phenotype upon activation of human eosinophils have been 
observed and include a decrease in cell density , differential expression of cell surface 
markers and enhanced adhesion , respiratory burst , bioactive lipid release and 
degranulation (Busse et al. , 1996; Carlson et al. , 1993; Takafuji et al. , 1991; Takafuji et 
al., 1996). Although the mechanisms which regulate human eosinophil degranulation 
are complex, the process may be divided into two distinct steps : 1) priming of 
eosinophils predisposes the cell to generate a specific response without the priming 
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agent itself inducing the response and 2) activation of eosinophil degranulation by a 
secretagogue leading to the release of cytotoxic granule proteins. The priming event is 
required for optimal release of granule proteins. Dissection of the role of molecules 
involved in -eosinophilic inflammation suggest that cytokines and chemokines are 
primarily priming agents (Alam et al. , 1993; Carlson et al., 1993; Fujisawa et al., 1990; 
Rot et al., 1992; Takafuji et al., 1996) whereas immunoglobulins, complement 
fragments and lipid mediators are secretagogues (Abu-Ghazaleh et al., 1989; Kaneko 
et al., 1995b; Khalife et al., 1986; Khalife et al., 1985; Kroegel et al., 1988; Kroegel et 
al., 1989; Takafuji et al., 1994; Takafuji et al., 1998). The engagement of adhesion 
systems is an essential co-stimulatory stimulus (Horie and Kita, 1994; Kaneko et al., 
1995a) and will be a recurring theme. 
1.6.1 Cytokines 
Cytokines regulate the differentiation, migration and activation of leukocytes. Various 
studies have demonstrated a role for both Th 1 and Th2 cytokines in the regulation of 
eosinophil activation. While certain cytokines served as a direct degranulation signal, 
others had a priming effect and some cytokines had an inhibitory effect on eosinophil 
degranulation. 
1.6.1.1 JL-5 
Eosinophil biology has focused attention towards the cytokines IL-3, IL-5 and GM-CSF 
because these molecules are implicated in the maturation of eosinophil progenitors 
and provide survival signals for eosinophils. These cytokines are also associated with 
Th2 immunity which regulates eosinophilia and the allergic response. IL-5 may serve 
as both a factor which primes human eosinophils for degranulation and as a 
secretagogue. Pre-incubation with IL-5 enhanced, in a dose- and time-dependent 
mechanism, the immunoglobulin-induced degranulation of eosinophils (Fujisawa et al., 
1990; Kita et al., 1992). A similar effect was observed when monitoring the release of 
ECP after stimulation with the complement proteins C3a, C3b and C5a (Carlson et al., 
1993; Takafuji et al. , 1996). The mechanism of IL-5 priming may be to enhance 
eosinophil adhesion which activates signaling pathways regulating the degranulation 
process (Fujisawa et al., 1997; Kato et al., 1998a). The role of I L-5 in modulating 
granulocyte degranulation is specific for eosinophils because neutrophil degranulation 
as measured by the release of myeloperoxidase and lactoferrin is unaffected by IL-5 
pre-treatment (Carlson et al., 1993). Thus , a potential mechanism exists at sites of 
inflammation to regulate the degranulation of specific granulocyte populations. 
16 
The priming of eosinophil degranulation by IL-5 is a very rapid response. During this 
period, IL-5 is unable to serve as a secretagogue. However, chronic exposure of 
human eosinophils to IL-5 leads to the release of granule proteins. After 3 days in 
culture meditim supplemented with IL-5, eosinophils had secreted significant amounts 
of all granule proteins with only 59°/o of the total MBP remaining in the granules (Kita et 
a/., 1992). Additional degranulation of eosinophils occurred up to day 7. Importantly, 
the morphology of the eosinophils was characteristic of activated eosinophils present in 
inflammatory disorders. Although IL-5 can induce the secretion of granule proteins, the 
kinetics of this process and the potency of IL-5 suggest that the principal role of this 
cytokine in relation to degranulation at sites of inflammation is to enhance the response 
of eosinophils to other stimuli (Fujisawa et al., 1997; Horie et al., 1996; Kita et al., 
1992). Furthermore, transgenic mice overexpressing IL-5 have a normal phenotype 
aside from the accentuated eosinophilia (Dent et al., 1990). This in vivo observation 
supports the notion that additional signals (to I L-5) are required for eosinophil 
degranulation. 
1.6.1.2 IL-3 and GM-CSF 
Both IL-3 and GM-CSF enhanced the degranulation of human eosinophils in response 
to different stimuli. IL-3 synergized with C3a and C5a to induce ECP release from 
eosinophils (Takafuji et al., 1996). However, in contrast to IL-5, IL-3 had a marginal 
effect on C3b-induced eosinophil degranulation (Carlson et al., 1993). This differential 
priming effect of IL-3 and IL-5 suggests that priming agents regulate separate signaling 
pathways (further discussed in section 1.6.8.1- Cytokine priming: IL-4 and IL-5 
signaling pathways). The degranulation of eosinophils in response to immunoglobulins 
was enhanced by priming eosinophils with either IL-3 or GM-CSF (Fujisawa et al., 
1990). Notably, GM-CSF was the only one of the three cytokines which demonstrated a 
potent secretagogue effect on human eosinophils (Carlson et al., 1993; Fujisawa et al., 
1990). The efficiency of GM-CSF is similar to secretory (s)lgA complexed to beads and 
platelet activating factor (PAF) which are among the most potent degranulation stimuli 
reported (Horie et al. , 1996). Furthermore, GM-CSF required the adhesion of 
eosinophils via a ~2-integrin dependent mechanism to induce eosinophil degranulation 
(Horie and Kita, 1994). 
1.6.1.3 IL-4 and IL-13 
IL-4 and IL-13 have been directly implicated in the regulation of immunological 
processes underlying the asthmatic phenotype. These cytokines possess common 
functions as they share the IL-4Ra receptor subunit. Effects on T- and 8-lymphocyte 
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biology, endothelial cells and AHR are well documented (Bochner et al., 1995; Grunig 
et al., 1998; Punnonen et al., 1993; Schleimer et al., 1992; Swain et al., 1990; 
Venkayya et al., 2002; Wills-Karp et al., 1998; Yang et al., 2001). However, 
investigations focusing on the role of IL-4 and IL-13 in directly regulating eosinophil 
degranulation are limited. A short exposure (1 hr) of human eosinophils to IL-4 had no 
or little effect on immunoglobulin-dependent degranulation. However, a longer 
exposure led to the down-regulation of lgG receptors along with a corresponding 
decrease in lgG-mediated degranulation (Baskar et al., 1990). The effect of IL-4 on 
FcR is specific for the lgG receptors as both the expression of lgE receptors and its 
modulation of eosinophil degranulation remained intact after IL-4 treatment (Baskar et 
a/., 1990). Independent investigations monitoring the effect of IL-4 on human eosinophil 
rosette formation on lgG- and lgA- coated beads confirmed that transient exposure to 
IL-4 has little effect on FcyR activation. However, IL-4 can stimulate lgA binding to the 
FcaR on the surface receptors (Bracke et al., 1997). Since lgA is a potent eosinophil 
secretagogue (Abu-Ghazaleh et al., 1989), IL-4 may prime lgA-mediated eosinophil 
degranulation. However, this hypothesis has yet to be tested. IL-13 has also been 
implicated in the regulation of eosinophil activation (Luttmann et al., 1996). However, 
whether IL-13 can also regulate eosinophil degranulation remains unresolved. 
1.6.1.4 TNF-a 
TNF-a is another cytokine which is up-regulated during allergic diseases. The effects 
of TNF-a on the pathogenesis of disease may rely on its modulation of eosinophil 
activation. Although TNF-a did not directly induce degranulation, it enhanced the 
stimulatory effects of IL-5 and serum opsonized particles on human eosinophil 
secretory pathways (Egesten et al., 1998). 
1.6.1.5 TGF-{31 and IFN-y 
While certain cytokines may prime eosinophil function, other cytokines may serve as 
negative regulators of eosinophil degranulation . Certain cytokines expressed during a 
Th1 immune response serve to suppress Th2 driven immunological networks. Th1 
cytokines with an inhibitory role in eosinophil degranulation include TGF-~1 and 
interferon (IFN)-y. The latter down regulated the secretion of EON from slgA activated 
human eosinophils (Fujisawa et al., 1990). 
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1.6.1.6 JL-1/3 
Another class of cytokines exists whereby the molecules have a dual role in enhancing 
and suppressing eosinophil secretory pathways. While IL-1 B had no effect on EON 
release, it inhibited the release of B-glucuronidase and arylsulfatase human eosinophils 
stimulated with lgG but enhanced the secretion of these enzymes after lgE stimulation 
(Baskar and Pincus, 1992). 
1.6.1.7 Other cytokines 
Additional cytokines produced during a Th1 and Th2 immune response have been 
analyzed for their effects on human eosinophil degranulation. A number of cytokines 
had neither an enhancing nor a suppressing effect on degranulation. IL-2, IL-6, and IL-
8 had no effect on eosinophil degranulation (Fujisawa et al., 1990; Horie et al., 1996). 
In summary, the effects of cytokines on eosinophil activation are complex. While 
certain cytokines may influence the pathogenesis of allergic diseases via the regulation 
of eosinophil effector functions, other cytokines regulate disease processes in an 
eosinophil-independent mechanism. 
1.6.2 Chemokines 
The principal function of chemokines is to attract circulating leukocytes into tissues and 
subsequently, direct the migration of the cells to sites of inflammation. A number of 
chemokines which regulate the migration of eosinophils to mucosal surfaces have 
been identified. Interestingly, a subset of these chemokines may also modulate 
eosinophil effector functions. 
Chemokines are classified principally into two families called the C-C chemokines 
where the two cysteine residues are adjacent while the C-x-C chemokines have a 
single amino acid separating the two cysteine residues (Baggiolini and Dahinden, 
1994). Members of the C-x-C family include IL-8, MIP-2, epithelial neutrophil-activating 
protein (ENA)-78 and interferon-inducible protein (IP)-10. These molecules affect 
mainly the function of neutrophils. It is the C-C chemokines which have sustained the 
greatest interest in studies of diseases associated with an eosinophilia because of their 
effect on eosinophil functions (Rothenberg et al. , 1999). RANTES, eotaxin-1 , eotaxin-2, 
eotaxin-3, MIP-1 a, monocyte chemotactic protein (MCP)-2 , MCP-3 and MCP-4 are all 
C-C chemokines. 
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To date, only a few studies have reported any effect of chemokines on eosinophil 
activation with a focus on the up-regulation of CD11 b expression and/or oxygen radical 
production. Specific chemokines such as eotaxin-1 and -2 and RANTES have been 
shown to induce a respiratory burst in human eosinophils (Elsner et al., 1998; Rot et 
al., 1992; Tenscher et al., 1996). With regards to eosinophil degranulation, eotaxin-1, 
RANTES and MIP-1 a induce the release of cytotoxic granule proteins by human 
eosinophils whereas other chemokines such as MIP-1 ~, MCP-1 and IL-8 were 
ineffective in causing the release of ECP (Alam et al., 1993; EI-Shazly et al., 1998; 
Horie et al., 1996; Rot et al., 1992). However, the mechanism by which chemokines 
regulate eosinophil effector functions remains poorly defined. 
1.6.3 lmmunoglobulins 
Elimination of a parasitic infestation is associated with the production of antigen-
specific immunoglobulins and an eosinophil-rich inflammatory response. Since the 
opsonized particle is non-phagocytosable, other effector mechanisms are required for 
the removal of parasites. In vitro experiments demonstrated that eosinophils can 
secrete cytotoxic molecules including the cationic proteins on the surface of parasites 
(Butterworth, 1984). Hence, the stimulus inducing the release of the cytotoxic 
mediators was hypothesized to be immunoglobulins, which interact with specific Fe 
receptors at the surface of eosinophils. 
1. 6.3.1 lgG, lgA and slgA 
Several laboratories have analyzed the efficacy of a large number of antibody isotypes 
in activating human eosinophil degranulation. Although the antibody isotypes lgl\.~ and 
lgD had little effect on eosinophil effector functions, lgA, slgA and lgG induced the 
release of granule contents by eosinophils (Abu-Ghazaleh et al., 1989; Kaneko et al., 
1995b; Khalife et al., 1985). The immunoglobulin-induced eosinophil degranulation 
may be enhanced by priming factors and is dependent on the ligation of the ~2 integrin, 
Mac-1(Fujisawa et al., 1990; Kaneko et al., 1995a; Kita et al., 1992). 
Interestingly, the most potent immunoglobulin was slgA (Abu-Ghazaleh et al., 1989). 
The secretory component is crucial for the difference in potency observed with lgA and 
lgG (Motegi and Kita, 1998). While the secretory fragment has little effect on its own, it 
acts synergistically with other agonists such as cytokines and immunoglobulins to 
induce eosinophil degranulation (Motegi and Kita, 1998). 
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1.6.3.2 lgE 
Atopic diseases are characterized by elevated levels of both total and antigen-specific 
lgE antibodies, which correlate with disease severity (Sears et al. , 1991 ). The principal 
role of lgE is -the activation of histamine release from mast cells and basophils (Galli et 
al., 1991 ). lgE may also affect disease processes by regulating eosinophil function 
since human eosinophils express lgE receptors including the low- (FccRII) and high-
affinity (Fc£RI) lgE receptors as well as another lgE binding molecule, Mac-2 (Capron 
et al., 1986; Gounni et al. , 1994; Grangette et al., 1989; Truong et al. , 1993). Moreover, 
lgE levels are associated with eosinophilia and Fc£RI positive eosinophils are present 
in the tissues of atopic patients (Barata et al., 1997; Rajakulasingam et al. , 1998; Ying 
et al., 1998). However, the functional significance of lgE receptor expression by 
eosinophils remains a controversial issue. 
The low expression levels and the localization of lgE receptors within eosinophils may 
be underlying this controversy. Emerging evidence suggests that although human 
eosinophils express Fc£Rs, these receptors are predominantly localized intracellularly 
and only a small fraction of the Fc£R pool is present at the cell surface (Kayaba et al., 
2001; Kita et al., 1999; Smith et al., 2000). In addition , the expression levels of FccRs 
on human eosinophils are dependent on the concentration of lgE in the 
microenvironment (Kayaba et al., 2001; Kita et al., 1999). Hence, the intracellular pool 
of FccRs might be required for a rapid cellular response by eosinophils to 
immunological challenges. Although the surface expression is very low, these 
receptors can trigger the release of cytokines, induce antibody-dependent cellular 
cytotoxicity towards helminthes and stimulate eosinophil degranulation (Dombrowicz et 
a/., 2000; Gounni et al. , 1994; Kayaba et al., 2001 ; Khalife et al. , 1986; Khalife et al. , 
1985; Tomassini et al. , 1991 ). 
The source of eosinophils might be another critical determinant in certain experimental 
models . Firstly, there exists a discrepancy in Fc£R expression by eosinophils from 
various species. While both human and rat eosinophils express functional Fc£R, mouse 
eosinophils do not express, at the messenger (m) RNA (ribonucleic acid) nor the 
protein level , Fc£Rs (de Andres et al. , 1997; Dombrowicz et al. , 2000). Furthermore, 
since the expression of Fc£Rs on the cellular surface is dependent on lgE 
concentrations (Kayaba et al., 2001 ; Kita et al., 1999), differences in lgE levels from 
patient to patient adds another degree of complexity . Finally , investigators have shown 
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that hypodense eosinophils but not normodense eosinophils appear to respond to lgE 
stimulation (Khalife et al., 1986). 
In general, the data implicate lgE as a mediator of eosinophil degranulation . Khalife 
and colleagues showed that cytophyllic lgE induces EPO release specifically in 
hypodense eosinophils from filariasis-infected patients which correlates with other 
studies that also failed to observe an lgE mediated degranulation in normodense 
eosinophils (Abu-Ghazaleh et al., 1989; Khalife et al., 1986). In addition , eosinophils 
isolated from allergic patients also released EPO in response to lgE stimulation 
(Tomassini et al., 1991). However, the specific contribution of lgE stimulation to 
eosinophil activation remains unclear. Mast cells and basophils are more responsive to 
lgE than eosinophils (Kita et al., 1999). Furthermore, eosinophils released less EON in 
response to lgE in comparison to lgG (Kaneko et al., 1995b; Kita et al., 1999). In light 
of current knowledge, additional studies are required to characterize the functional 
heterogeneity · within eosinophil populations and identify physiological and pathological 
circumstances when lgE plays an active role in stimulating eosinophil effector 
functions. In addition, the effect of lgE on other cellular functions of eosinophils should 
be investigated. Notably, lgE can enhance antigen internalization and presentation to T 
cells by APCs (Maurer et al., 1995; Maurer et al., 1996; Mudde et al., 1995). Thus, the 
primary role of FcER on eosinophils may not be to induce cellular activation but rather 
to promote its function as an APC. 
1. 6.3.3 Role of Antigen 
lmmunoglobulin-induced degranulation of human eosinophils may be dependent on 
antigen specificity. In certain experimental systems, binding to immunoglobulins was 
insufficient to induce eosinophil degranulation and the presence of the antigen was 
necessary (Khalife et al., 1985). As a consequence, only low levels of granule proteins 
were released by eosinophils when stimulated with antibody alone, antigen alone, an 
irrelevant antigen and an antibody recognizing an unrelated antigen (Khalife et al., 
1985). Furthermore, cytophilic immunoglobulins present on the surface of circulating 
and tissue-dwelling eosinophils stimulate degranulation only upon ligation with the 
antigen (Khalife et al., 1986; Tomassini et al. , 1991 ). Hence, a mechanism regulat ing 
the release of granule proteins by eosinophils at sites of inflammation exists and 
prevents the premature degranulation of circulating eosinophils as the cells encounter 
immunoglobulins within blood . Although eosinophil degranulation was induced in other 
experimental models by immunoglobulins in the absence of antigen , this cellular 
response occurs only when the stimulus is immobilized to a surface (Kaneko et al. , 
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1995a). Under these circumstances, the non-phagocytosable surfaces may serve only 
as a substitute for the physiological antigen. Therefore, the antigen may activate 
eosinophil degranulation via 2 mechanisms: 1) the binding of the antibody· t.o the 
antigen may --cause a conformational change in the structure of the immunoglobulin 
permitting the transduction of signals via the Fe receptor and, 2) the antigen serves as 
a surface for cellular adhesion, a necessary co-stimulatory signal for eosinophil 
activation. 
1.6.4 Lipid mediators and Steroids 
During an inflammatory response, numerous lipid mediators are secreted by effector 
cells. These molecules are principally the products of arachidonic acid metabolism 
which include prostaglandins, leukotrienes and lipoxins. Other important bioactive lipids 
are PAF and steroids. Importantly, the lipids have been directly implicated in the 
pathogenesis of allergic disorders (Chung and Barnes, 1991; Drazen, 1998; Page, 
1991 ). Lipids may potentially affect disease processes by activating eosinophil effector 
functions. 
1. 6.4.1 Mast cell-derived factors 
Mast cells are key effector cells in the early-phase response during allergic diseases 
and may secrete bioactive lipids to modulate the leukocyte subsets implicated in the 
late-phase response. Mast cells secrete prostaglandins, leukotrienes · and histamine 
upon cross-linking of FcERI with lgE-antigen complexes (Metcalfe et al. , 1997). When 
tested for the ability of various bioactive lipids to activate human eosinophils, only L TB4 
and PAF induced the release of ECP (Kroegel et al., 1988; Kroegel et al., 1989; 
Soyombo et al. , 1994; Takafuji et al., 1998). Furthermore, PAF has been shown to be 
one of the most potent stimuli of eosinophil degranulation . ~2-integrin engagement is 
also essential for PAF-mediated eosinophil degranulation (Horie and Kita , 1994). 
Interestingly, prostanoids which signal through the DP and EP receptors inhibited the 
release of ECP by eosinophils (Butchers and Vardey, 1990). 
1.6.4.2 Priming by eicosanoids 
Other bioactive lipids prime eosinophil degranulation . Indeed , certain eicosanoids 
enhance the degranulation of human eosinophils in response to various secretory 
stimuli. Although 5-oxo-eicosatetraenoate (ETE) induces a weak degranulation 
response within eosinophils , it could enhance the secretory signals elicited by PAF, 
C5a and L TB4 (O'Flaherty et al., 1996). Derivatives of 5-oxo-ETE such as 5-oxo-15-
hydroxy-ETE and 5-hydroxy-ETE provided a milder response while other eicosanoids 
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were inactive under all conditions (O'Flaherty et al., 1996). 
1. 6.4.3 Sex hormones 
A link between the prevalence of asthma during pregnancy suggested a role for sex 
hormones in regulating eosinophil function. Individually the hormones ~-estradiol, 
progesterone and testosterone had no effect on eosinophil degranulation (Hamano et 
al., 1998). However, the combination of ~-estradiol and progesterone induced 
eosinophil effector functions (Hamano et al., 1998). Unfortunately, the study did not 
investigate a possible role for the sex hormones as priming agents. Adhesion 
processes play a crucial role in the regulation of eosinophil activation. Since the sex 
hormones modulate the adhesive properties of eosinophils (Hamano et al., 1998), it is 
possible that sex hormones may enhance or inhibit eosinophil degranulation stimulated 
by a strong secretagogue. 
1.6.5 Complement fragments 
Complement proteins play an obscure role during immunological responses. Several 
receptors for complement factors are present on eosinophils. Engagement of these 
receptors stimulated eosinophil degranulation. Serum-coated beads induced the 
release of ECP from human eosinophils (Carlson et al., 1993; Winqvist et al., 1984). 
Furthermore, purified complement fragments C3a, C3b and C5a all stimulated the 
release of granule proteins (Carlson et al., 1993; Takafuji et al., 1996; Takafuji et al., 
1994). Eosinophil degranulation stimulated by serum, C3a and C5a could be enhanced 
by IL-3 and IL-5 (Carlson et al., 1993; Takafuji et al., 1996). In conclusion, complement 
proteins may potentiate eosinophil degranulation during an inflammatory response. 
1.6.6 Eosinophil cytotoxic granule proteins 
Although the cationic granule proteins possess cytotoxic properties, specific molecules 
have been shown to regulate secretory pathways of mast cells, neutrophils, basophils 
and platelets through a non-cytolytic mechanism (Moy et al., 1990; O'Donnell et al., 
1983; Rohrbach et al., 1990; Zheutlin et al., 1984). Both MBP and EPO, but not ECP, 
can also stimulate eosinophil degranulation independently of their cytolytic properties 
(Kita et al., 1995). Importantly, the response of human eosinophils to EPO and MBP is 
a dose-, temperature- and calcium-dependent response and could be inhibited by 
various pharmacological agents (Kita et al. , 1995). Therefore, an autocrine mechanism 
exists to maintain activation signals upon the stimulation of eosinophil degranulation by 
exogenous agonists. 
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1.6. 7 Adhesion molecules 
Adhesion molecules regulate the selective recruitment of leukocytes to sites of 
inflammation in allergic diseases. Notably, tissue eosinophilia-associated with 
experimental -asthma was abolished by inhibitory antibodies targeted against integrins 
expressed by eosinophils and in mice-deficient for ligands of these integrins (Broide et 
al., 1998; Nakajima et al., 1994). In addition, integrin-mediated cellular adhesion may 
also play an important role in modulating human eosinophil activation in response to 
secretagogues. Evidence supporting this notion include kinetic studies depicting that 
cellular adhesion precedes e_osinophil degranulation, soluble stimuli fail to induce 
eosinophil degranulation whereas immobilized ligands activate the release of EON and 
inhibition of cellular adhesion by stirring the cell culture prevents PAF and GM-CSF 
stimulation of eosinophil degranulation (Horie and Kita, 1994; Kaneko et al., 1995a). 
1.6.7.1 Mac-1 
lntegrins are heterodimers composed of an a- and a ~-subunit. Eosinophils express 
several members of the ~1 and ~2 integrin families including very-late antigen-4 (VLA-4; 
a4/~1), lymphocyte function-associated antigen-1 (LFA-1; aL/~2) and Mac-1 (aM/~2). The 
expression of the adhesion molecules is modulated by the activation status of 
eosinophils (Li et al., 1996). Notably, Mac-1 is up-regulated in eosinophils from allergic 
patients and further increased upon migration to sites of allergen provocation (Busse et 
al. , 1996). Correlation of the expression profile of Mac-1 and eosinophil activation 
suggests a potential role for this integrin in modulating eosinophil effector functions. 
Indeed , antibodies targeted against the aM and ~2 subunits but not antibodies 
recognizing the aL subunit of LFA-1 inhibited human eosinophil degranulation 
stimulated by a range of physiological stimuli (Horie and Kita, 1994; Kaneko et al., 
1995a). Moreover, direct ligation of Mac-1 induced intracellular signaling events 
culminating in the release of EON (Kato et al., 1998a; Kato et al. , 1998b). 
Mac-1 may interact with a number of ligands including iC3b, fibrinogen , intercellular 
adhesion molecule (ICAM)-1 and ICAM-2. Several molecules may modulate ~rintegrin 
dependent eosinophil degranulation . Although human eosinophils do not 
spontaneously bind to ICAM-1 , GM-CSF induced cellular adhesion to this substrate 
which led to activation of eosinophil effector functions including degranulation (Nagata 
et al., 1998). Furthermore, a report depicted the potential of soluble ICAM-1 to induce 
human eosinophil secretion of granule contents (Chihara et al., 1995). However, 
ICAM-1 may not serve as the primary ligand in vivo. Oegranulation of human 
eosinophils co-cultured with respiratory syncytial virus-infected pulmonary epithelial 
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cells was a ~rintegrin dependent but ICAM-1 independent process despite ICAM-1 
expression being up-regulated in virus-infected epithelial cells (Olszewska-Pazdrak et 
al., 1998). Components of the extracellular matrix may also modulate Mac-1 activation 
of eosinophils. Fibrinogen synergistically activated human eosinophil degranulation in 
the presence of lgG tethered to beads (Kaneko et al., 1995a). Hence, both extracellular 
matrix proteins or cell-bound ligands may serve as a counterpart for Mac-1 in vivo. 
1.6.7.2 ICAM-1 
Although ICAM-1 may modulate eosinophil degranulation through its interaction with 
Mac-1, it may also directly affect intracellular signaling pathways linked to eosinophil 
degranulation. ICAM-1 is absent in peripheral blood eosinophils but its expression is 
induced upon migration of eosinophils to sites of allergic disease (Hansel et al., 
1991 a). The expression of ICAM-1 on the surface of human eosinophils can be up-
regulated in vitro by GM-CSF and TNF-a leading to a subsequent release of granule 
proteins (Horie et al., 1997a). Treatment with a blocking antibody raised against ICAM-
1 significantly inhibited eosinophil degranulation (Horie et al., 1997a). 
1.6.7.3 VLA-4NCAM-1 
Eosinophils express VLA-4 which through its interaction with vascular cell adhesion 
molecule (VCAM)-1 on endothelial cells regulates the recruitment of eosinophils to 
sites of allergic inflammation (Nakajima et al., 1994). This adhesion system plays a 
selective role in eosinophil-driven diseases since neutrophils do not express VLA-4. 
Unfortunately, the evidence linking both adhesion molecules to eosinophil activation is 
controversial and requires additional experiments to delineate the accurate effects of 
VLA-4 and VCAM-1. In two independent reports, Nagata and colleagues (Nagata et al., 
1995; Nagata et al., 1998) demonstrated that adhesion of human eosinophils to VCAM-
1 coated wells induced superoxide production. Furthermore, blocking antibodies to 
both ~1 and ~2 integrins inhibited the respiratory burst. GM-CSF enhanced the effect of 
VCAM-1 mediated eosinophil adhesion on the production of reactive oxygen species 
(Nagata et al., 1998). However, this enhancement was inhibited only by blocking 
antibodies against ~2 integrins (Nagata et al., 1998). With regards to degranulation, 
VCAM-1 required GM-CSF as a co-stimulatory molecule to induce the secretion of 
EON by human eosinophils (Nagata et al., 1998). Once again, this effect was only 
inhibited by blocking antibodies against ~2 integrins. How signaling pathways 
downstream of ~2 integrins cooperate with the VLA-4NCAM-1 complex in adherent 
eosinophils remains unclear. 
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1. 6. 7.4 Extracellular matrix 
Eosinophils adhere to fibronectin in a VLA-4 dependent mechanism . However, 
divergent experimental conditions have led to contradictory results as to the effect of 
this adhesion-event on eosinophil activation. In an initial study, Neeley and colleagues 
(Neeley et al., 1994) demonstrated that VLA-4-mediated adhesion to fibronectin primed 
human eosinophils to degranulate in response to a combination of N-formyl-methionyl-
leucyl-phenylalanine (fMLP) and cytochalasin B. Unfortunately, the effects of the 
pharmacological agent cytochalasin B are ill-defined and may modify the behavior of 
cells. Other investigators have demonstrated that PAF, IL-5 and C5a but not slgA-
induced EON release was lower in fibronectin, laminin and collagen, compared to 
human serum albumin, coated wells (Kita et al., 1996). However, eosinophil 
degranulation was not affected by coating wells with fibrinogen in lieu of human serum 
albumin (Kita et al., 1996). The inhibitory effects of fibronectin, laminin and collagen are 
associated with their ability to bind ~1 integrins. An equilibrium between ~1 and ~2 
engagement may be a key regulatory mechanism for eosinophil degranulation. 
In conclusion, eosinophil degranulation requires cellular adhesion via ~2 integrins but 
the role of ~1 integrins in regulating eosinophil activation remains elusive. Additional 
experiments aimed at understanding the cross-talk between different adhesion 
systems is necessary to delineate the mechanisms by which adhesion molecules 
modulate eosinophil effector functions. 
1.6.8 Intracellular signaling pathways 
The intracellular signaling pathways which regulate eosinophil degranulation are poorly 
defined. In general, only common second messengers and the protein families 
implicated in eosinophil activation have been described for certain agonists. However, 
the specific protein family members remain largely unknown. This review will focus on 
the signal transduction pathways modulating Fe receptor activation by cytokine priming 
and immunoglobulin-induced degranulation of human eosinophils (Fig.1.4). 
1.6.8.1 Cytokine priming: IL-4 and IL-5 signaling pathways 
A potential priming mechanism of eosinophil degranulation is the regulation of the 
affinity or avidity of immunoglobulin receptors by Th2 cytokines. IL-4, IL-5 and GM-CSF 
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FIGURE 1.4- Intracellular signalling pathways regulating human eosinophil activation. 
A. Differential downstream effectors from the IL-4R and IL-5R result in the activation of 
specific immunoglobulin receptors in primed eosinophils. B. Secretagogues such as 
immunoglobulins activate a signalling pathway which induces the production and 
secretion of PAF by eosinophils. The stimulation of a PAF receptor further propagates 
the signal via classical effectors of G-protein-coupled receptors prompting the 
eosinophil to undergo degranulation. 
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enhanced the binding of eosinophils to immunoglobulin-coated beads without altering 
the expression levels of the receptors (Bra eke et al., 1997; Koenderman et al. , 1993). 
Furthermore, differential effects were observed for the regulation of FcyRII and FcaR 
by cytokines. --While IL-5 and GM-CSF increased the binding of eosinophils to lgG and 
lgA-coated beads, IL-4 primed eosinophils for an interaction with lgA and not lgG 
(Bra eke et al., 1997). 
The difference in activation properties of IL-4 and IL-5 relies on the intracellular 
signaling pathways employed by the receptors (Fig.1.4A). Although cytok.ine receptors 
primarily signal via Jak-Stat pathways, current evidence suggests that these pathways 
do not play a critical regulatory role in eosinophil activation but other cellular functions 
such as eosinophil survival (Pazdrak et al., 1998). However, both IL-4 and IL-5 
positively regulate the function of FcaR by signaling via a pathway involving 
phosphoinositol-3-kinase (P13K) , which directs the activation of p38 MAP kinase 
(Bracke et al., 1998; Coffer et al., 1998). In contrast, the activation of FcyRII is affected 
by means of the p21 ras-Raf1-MEK-ERK2 pathway (Bracke et al. , 1998; Coffer et al., 
1998). Importantly, the Raf-1 kinase and its downstream effectors may be required for 
the activation of eosinophils, in general, since this pathway did not only affect FcyRII 
activation but also Mac-1 expression and degranulation (Pazdrak et al. , 1998). The 
inability of IL-4 to activate the latter signaling cascade explains its lack of involvement 
in regulating FcyRII function (Bracke et al., 1998). 
1.6.8.2 lmmunoglobulin induced eosinophil degranulation 
After initial priming events, human eosinophils will release optimal levels of granule 
proteins when stimulated by a secretagogue. lmmunoglobulins are potent secretory 
signals for eosinophils. In particular, lgG and lgA induce eosinophil degranulation via 
the FcyRII and FcaR, respectively (Abu-Ghazaleh et al., 1989; Kaneko et al., 1995b; 
Motegi and Kita , 1998). Recent reports have provided additional insight into the 
molecular events downstream of these receptor systems (Fig.1.48) . 
Activation of Fe receptors leads to a rapid induction of protein-tyrosine phosphorylation 
with a subset of these proteins potentially phosphorylated by the protein-tyrosine 
kinase Fgr (Kato et al. , 1995; Kato et al. , 1997; Kita et al., 1994). Although FcR are not 
G-protein coupled receptors , pertussis toxin , an inhibitor of the Gai subunit of 
heterotrimeric proteins, inhibited eosinophil degranulation (Kita et al. , 1991 b; Kita et al., 
1994). This observation led investigators to hypothesize and demonstrate that the 
signal is subsequently transduced to PLA2 , which induces the synthesis of PAF 
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(Bartemes et al. , 1999). The endogenous production of PAF is essential for eosinophil 
degranulation. Eosinophils express two receptors for PAF which are seven 
transmembrane domain, G-protein coupled receptors. However, it is unknown whether 
PAF must be secreted to subsequently activate a receptor on the cell surface or 
whether PAF can directly activate an intracellular receptor molecule. The activation of a 
PAF receptor couples the heterotrimeric protein to downstream effectors , including 
phospholipase C (PLC) (Kita et al., 1991 b). The hydrolysis of phosphoinositols 
catalyzed by PLC results in the production of inositol 1,4,5-triphosphate (IP3) and 1,2-
diacylglycerol (DAG) which, respectively, activate an intracellular increase in calcium 
and protein kinase C (PKC). These mediators appear to play important roles in the 
process of eosinophil degranulation as the addition of pharmacological agents such as 
calcium ionophores and phorbol esters to eosinophil cultures induces release of 
granule proteins (Egesten et al., 1993; Fukuda et al., 1985). The regulated exocytosis 
of granule proteins may require vesicle (v)- soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE)s and target (t)-SNAREs, critical effector 
molecules in the fusion of vesicles with the plasma membrane. Vesicle-associated 
membrane protein (VAMP)-2 has been identified as an important v-SNARE in the 
modulation of piecemeal degranulation but the t-SNAREs involved in eosinophil 
degranulation have yet to be identified (Hoffmann et al., 2001; Lacy et al., 2001) . Two 
potential candidates include synaptosomal-associated protein (SNAP)-23 and syntaxin-
4 (Logan et al., 2002). PKC and calcium may relate their signals to v- and t-SNAREs, 
the terminal effector proteins in the process of exocytosis. 
Although the signal transduction pathways regulating eosinophil degranulation are 
poorly defined , the advent of eosinophil cell lines and novel methodologies for the 
manipulation of primary eosinophils will lead to additional breakthroughs. 
1.6.9 Model of eosinophil degranulation 
The signaling networks regulating eosinophil degranulation are complex and remain 
only partially understood. However, a model of eosinophil degranulation (Fig .1.5) may 
be developed based on current knowledge. 
The mechanisms regulating eosinophil degranulation encompass 5 steps which are 
required for optimal release of granule proteins: 1) eosinophils are primed by cytokines 
and/or chemokines; 2) secretagogues such as immunoglobulins , bioactive lipids or 
complement fragments activate eosinophil secretory pathways; 3) intracellular signaling 
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FIGURE 1.5- Model of eosinophil degranulation. Eosinophil degranulation is regulated by several mechanisms which are 
required for optimal release of granule contents: 1) eosinophils are primed by cytokines (e.g. IL-5) and chemokines; 2) 
eosinophils are activated by secretagogues such as immunoglobulins; 3) these secretagogues induce the endogenous 
production of PAF which signals in an autocrine or paracrine manner; 4) adhesion via J32- integrins is a required co-stimulatory 
signal; 5) once secreted, MBP and EPO can further stimulate eosinophil degranulation. 
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cascades downstream of the receptors for secretagogues lead to the endogenous 
production of PAF which signals either via intracellular receptors or in an 
autocrine/paracrine manner; 4) the induction of eosinophil adhesion via ~2-integrins is 
an essential co-stimulatory pathway; 5) the cytotoxic cationic proteins released into the 
extracellular space can further stimulate the release of granule contents. 
This paradigm provides a mechanism for the tight control of eosinophil degranulation 
which is essential due to the cytotoxic properties of eosinophil-derived mediators. 
Optimal release of granule contents will only occur when all 5 signals are present 
during the inflammatory response. Unfortunately, eosinophil degranulation may be 
difficult to arrest once the process is initiated because of the autocrine signals 
generated by activated eosinophils. 
1.6.10 Anti-inflammatory drugs 
Numerous drugs have been marketed for their ability to suppress inflammatory 
responses associated with allergic diseases. The most popular therapeutic agents are 
the glucocorticoids, ~2-adenoreceptor agonists , the non-selective and selective 
phosphodiesterase inhibitors and H1 blockers . The mechanisms for the effect of these 
drugs on immune networks is poorly characterized. 
The contribution of eosinophils to the development of allergic disease has been 
appreciated only recently. Inhibitors of eosinophil function would provide a means for 
relief of symptoms associated with eosinophil-driven diseases. The drugs currently 
utilized for the treatment of asthma are being tested for a potential direct effect on 
eosinophil functions including chemotaxis , superoxide production , leukotriene 
synthesis and degranulation . The majority of drugs have no or little effect on eosinophil 
degranulation . The glucocorticoids, cetirizine, disodium cromoglycate , denbufylline and 
ketotifen were ineffective in inhibiting eosinophil secretory processes (Ezeamuzie and 
Al-Hage, 1998; Kita et al. , 1991 a; Meng et al. , 1997; Okada et al., 1994). However, 
glucocorticoids may play a role in regulating IL-5 signaling as the IL-5 enhancement of 
eosinophil degranulation was inhibited by cyclosporin A and rapamycin (Meng et al., 
1997). 
Certain molecules displayed an intermediate effect on eosinophil activat ion . 
Salbutamol and salmeterol were both effective inhibitors of superoxide generation 
stimulated by PAF (Ezeamuzie and Al-Hage , 1998) . However, the inhibition of 
eosinophil degranulation by salbutamol/ salmeterol was dependent on the 
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secretagogue. Both drugs reduced the level of EPO release induced by fMLP but had 
no effect on C5a-induced eosinophil degranulation (Ezeamuzie and Al-Hage, 1998). 
The compounds with the greatest potential in regulating eosinophil function include 
sulochrin , the ~2-adenoreceptor agonists formaterol and procaterol, and the 
phosphodiesterase inhibitors theophylline and isomethylxanthine (Eda et al., 1993; 
Ezeamuzie and Al-Hage, 1998; Ohashi et al. , 1998; Okubo et al., 1997). All molecules 
were effective inhibitors of eosinophil degranulation induced by the most potent 
physiological secretagogues including PAF and slgA. However, numerous studies 
suggest that the ideal strategy is the use of a combination of drugs which affect 
different components of the degranulation process. The inhibition of eosinophil 
degranulation by ~2-adenoreceptor agonists was enhanced by the addition of a 
phosphodiesterase inhibitor (Eda et al., 1993; Okubo et al., 1997). 
A number of drugs have demonstrated the potential to inhibit eosinophil effector 
functions . The development of more potent and specific inhibitors of eosinophil 
degranulation may be a potential method for reducing the severity of symptoms 
associated with allergic diseases. 
1.7 CONCLUDING REMARKS 
' Eosinophils are considered key effector cells in the pathogenesis of allergic diseases. 
One potential mechanism for eosinophils to affect disease processes is through the 
release of cytotoxic cationic proteins by a process called degranulation . Notably, an 
increase of eosinophil-derived mediators in allergic tissues often correlates with 
disease severity (Filley et al., 1982; Fujimoto et al., 1997; Lou is et al. , 2000). The 
immune networks regulating eosinophil activation include cytokines, lipid mediators , 
immunoglobulins, complement proteins and adhesion systems. Since animal models 
are widely employed to dissect the molecular and cellular mechanisms regulating 
allergic diseases, these models should reproduce disease processes occurring within 
human disorders. In limited studies , investigators have failed to detect eosinophil 
degranulation within the submucosa of allergic lungs of mice questioning the validity of 
utilizing this specie to model the contribution of eosinophils to the pathogenesis of 
allergic airways disease (Malm-Erjefalt et al., 2001 ; Stelts et al. , 1998). However, 
emerg ing evidence suggests that eosinophils can participate in the regulation of 
disease processes not solely in the submucosa but also in the airway lumen (Hisada et 
al. , 1999; MacKenzie eta/. , 2001 ; Mould eta/. , 1997; Shi eta/. , 2000; Tomkinson eta/. , 
2001 ). Therefore, this thesis describes a comprehensive investigation in the activation 
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status of eosinophils in a mouse model of allergic airways disease including potential 
reasons for the discrepancy in eosinophil degranulation within the lung submucosa of 
allergic mice and asthmatics. Animal models of experimental asthma may provide a 
tool to further elucidate the mechanisms regulating eosinophil activation in vivo. A 
better understanding of mechanisms modulating eosinophil degranulation may provide 
a platform for the development of novel therapeutic compounds for the treatment of 
allergic inflammatory diseases. 
Specific aims of this thesis-
1 )To determine whether eosinophils degranulate to contribute to the pathogenesis of 
disease in a mouse model of allergic airways inflammation. 
2)To compare the mechanism of degranulation between human and mouse 
eosinophils. 
3)To develop a method for the purification of eosinophils from the bone marrow, blood 
and airway lumen of allergic mice. 
Eosinophil degranulation in the allergic lung of 
mice primarily occurs in the airway lumen 
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2.1 INTRODUCTION 
Eosinophils are regarded as key effector cells in the pathogenesis of allergic diseases 
(Rothenberg, 1998; Wardlaw et al., 1995). These leukocytes may induce disease 
through the release of a range of pro-inflammatory molecules and cytotoxic proteins 
including MBP, EPO, and eosinophil ribonucleases from their granules. Notably, MBP-
1 has been associated with the induction of epithelial damage, edema and AHR to 
inhaled spasmogens (Frigas et al., 1980; Gundel et al., 1991; Hisamatsu et al., 1990; 
Uchida et al., 1993). Accordingly, the increased presence of eosinophils and their 
secreted products in the asthmatic lung often correlates with disease severity and 
exacerbation of disease (Filley et al., 1982; Fujimoto et al., 1997; Louis et al., 2000). 
Cationic cytotoxic proteins are stored in the secondary granules of eosinophils and 
their release, termed degranulation, may proceed via three mechanisms: i) classical 
exocytosis, whereby secondary granules directly fuse with the plasma membrane of 
the cell to release their entire contents into the extracellular environment (Lindau et al., 
1993; Nusse et al., 1990); ii) piecemeal degranulation, whereby small vesicles bud 
from the secondary granules and subsequently transport a subset of the granule 
proteins to the cell surface, resulting in the progressive loss of secondary granule 
constituents (Dvorak et al., 1992; Dvorak et al., 1991); and iii) cytolysis, a highly 
organized process of cell death where loss of the plasma membrane's integrity leads to 
the release of cellular contents (Erjefalt et al., 1998). These mechanisms of eosinophil 
degranulation have been well characterized by transmission electron microscopy and 
all three processes have been observed in tissues from patients suffering from a range 
of inflammatory disorders (Dvorak, 1994; Dvorak et al., 1993b; Erjefalt et al., 1998; 
Erjefalt et al., 1999). Notably, in airway tissues from atopic patients, piecemeal 
degranulation was predominantly observed, although some eosinophils released 
granule contents by cytolysis (Erjefalt et al., 1998; Erjefalt et al., 1999). 
Recently mouse models of CD4+ Th2 lymphocyte immunity have emerged as central 
tools to study disease mechanisms that underpin allergic disorders (Foster et al., 1996; 
Hamelmann et al., 1997; Hogan et al., 2001; Kumar and Foster, 2001 ). Mouse models 
of allergic airways disease display several characteristic features of human asthma and 
have been extensively employed to define eosinophil functions in pathogenesis (Foster 
et al. , 2001; Webb and Foster, 1999; Wills-Karp , 2000). Indeed , in mouse models of 
experimental asthma, the recruitment of eosinophils to the lung has been directly linked 
to the development of pathogenic features that are hallmarks of the disorder in humans 
(Foster et al., 1996; Hamelmann et al., 1999a; Justice et al. , 2003; Shen et al., 2003; 
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Tomkinson et al. , 2001) . However, attenuation (but not abolition) of eosinophil 
trafficking to the lung does not always correlate with inhibition of disease processes 
(Corry et al., 1996; Hessel et al. , 1997; Hogan et al., 1998) and eosinophil 
degranulation-- in the submucosa of the allergic lung of mice (Malm-Erjefalt et al. , 2001; 
Stelts et al., 1998) (a key feature of human disease (Erjefalt et al., 1998; Erjefalt et al. , 
1999; Filley et al. , 1982)) has not been observed. The failure to observe eosinophil 
degranulation has questioned the relevance of mouse models of allergic disease to 
understanding the contribution of eosinophils to allergic disorders (Malm-Erjefalt et al., 
2001 ). 
Although eosinophil degranulation is not evident in subepithelial regions of the lungs of 
allergic mice, MBP and EPO have been detected in cell free extracts taken from the 
bronchoalveolar lavage fluid (BALF) (Hisada et al., 1999; Mould et al., 2000; 
Tomkinson et al. , 2001 ). Interestingly, eosinophils residing in the airway lumen of 
allergic mice have been shown to actively participate in immune processes (MacKenzie 
et al., 2001; Shi et al., 2000). Collectively, these investigations suggest that eosinophils 
may selectively receive activation signals in the lumenal compartment. Notably, only 
limited studies have investigated the activation status of eosinophils in the lungs of 
allergic mice and these have focused on tissue-dwelling cells and not of those residing 
in the airway lumen (Hamelmann et al., 1999b; Malm-Erjefalt et al., 2001; Stelts et al., 
1998). 
In this investigation , we extend our characterization of the role of the eosinophil in the 
pathogenesis of allergic airways disease in mice by analyzing the ultrastructure and 
activation status of this cell as it migrates from the bone marrow to the airway lumen 
during inflammation. We detected cell-free EPO in respiratory secretions (BALF), and 
showed that eosinophils in the airway lumen are highly activated and release granule 
contents by piecemeal degranulation (the primary mechanism of degranulation in 
human asthmatic tissue) . Furthermore, we link eosinophil activation (evidenced by 
piecemeal degranulation and the presence of cell free EPO) in the airway lumen with 
enhanced airways reactivity to methacholine. We speculate that the differences in the 
degree and site of eosinophil activation/degranulation between mouse models of 
asthma and human diseased tissue may arise, in part , because of higher thresholds for 
the activation of the mouse leukocyte in response to secretagogues and also because 
of the acute (mouse) versus chronic (human) nature of the inflammatory processes. 
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2.2 MATERIALS AND METHODS 
2.2.1 Mice 
Male WT BALB/c, and strain matched IL-5 transgenic (Tg) mice (Ref. Dent et al., 1990; 
backcrossed to the 12th generation) (6 to 8 weeks old) were supplied by the pathogen-
free facility, John Curtin School of Medical Research, Australian National University. 
Mice were treated in accordance with The Australian National University Animal 
Welfare Guidelines. 
2.2.2 Induction of allergic airways disease 
Mice were sensitized by an i.p. injection of ovalbumin (OVA; Grade V, Sigma Chemical 
Co., St-Louis, MO, USA) on days O and 12, at a dose of 50 µg in 1 mg of Alhydrogel 
(CSL Ltd., Parkville, Australia) in isotonic saline (Foster et al., 1996). Nonsensitized 
mice received 1 mg of Alhydrogel in isotonic solutions (SAL). On days 24, 26, 28 and 
30, all groups of mice were exposed to an aerosol formed from a 1 °/o w/v solution of 
OVA in saline for 3 periods of 30 min, with a 30 min interval between each exposure. 
The aerosol was generated by a RapidFlow nebulizer bowl (Allersearch, Melbourne, 
Australia) (Foster et al., 1996). This regime produced maximal inflammatory cell 
numbers in the bone marrow, blood and pulmonary tissue (Ref. Foster et al., 1996; 
data not shown) . Cellular responses were characterized 16 h after the last aerosol 
exposure. 
2.2.3 Characterization of pulmonary inflammation 
Leukocytes recruited to the lungs of control and allergic mice were characterized in the 
BALF (Foster et al., 1996). Briefly, to lavage the lungs, the trachea was exposed, 
canulated with a blunt 18-gauge needle, and the lungs were washed twice with 1 ml of 
PBS. BALF was recovered and centrifuged for 5 min at 300 x g. The supernatant was 
stored at -70°C for assessment of EPO content. Leukocyte populations in BALF were 
identified according to standard morphology and quantified as previously described 
(Foster et al., 1996). Importantly, viability of leukocytes was always very high (>95°/o 
according to trypan blue assay). 
2.2.4 Collection and processing of samples for transmission electron 
microscopy 
Lung tissue and cells isolated from bone marrow, blood and BALF were processed for 
transmission electron microscopy. Bone marrow, blood and BALF cells and lung tissue 
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were isolated (six mice per group) by standard techniques (Foster et al. , 1996; Mould 
et al. , 1997; Mould et al., 2000; Webb et al., 2000) . Briefly , individual cell populations 
were pooled and the red blood cells were lysed usi.ng an ammonium chloride buffer 
(0.16 M NH4CI-, 0.17 M Tris pH 7.2) . Subsequently, the cell populations were washed in 
PBS containing 1 mM EDTA before being fixed in 2°/o glutaraldehyde in 0.1 M sodium 
cocadylate, pH 7 .4 at 4°C overnight. Isolated lung tissue (3x3x3 mm) was placed 
immediately in fixative (as above) and incubated at 4°C overnight. All samples were 
washed in 0.1 M sodium cocadylate buffer. The samples were postfixed in 1 °/o osmium 
tetroxide for 90 min, stained en bloc in 2°/o uranyl acetate, dehydrated in graded 
alcohol solutions and embedded in Spur's resin (ProSciTech, Australia). Sections 
(1 µn) were stained with Toludine Blue to identify intact regions of pulmonary tissue. 
Ultra-thin sections (80-85 nm) were cut on a Reichert-Jung Ultracut E ultramicrotome. 
The samples were stained with lead citrate before analysis using an Hitachi 
transmission electron microscope (H-7000; Hitachi, Japan). 
2.2.5 Quantification of eosinophil degranulation by transmission electron 
microscopy 
Initially, the number of eosinophils that were resting , degranulating or apoptotic were 
defined in various compartments . Degranulating eosinophils were then further 
delineated from one another based on the mechanism of granule protein release 
(exocytosis, piecemeal degranulation and cytolysis). Subsequently, the secondary 
granules of each eosinophil were counted and classified into four categories (see Fig. 
2.1: type I, intact; type 11, loss of crystal core; type Ill, loss matrix; and type IV, loss of 
both crystal core and matrix). The definitions for all groups are based on the method 
devised by Erjefalt et al. (Erjefalt et al. , 1998). The extent of degranulation was 
quantified by means of a degranulation index calculated using the following formula: 
Degranulation Index = 100 x (number of activated granules , types II to IV / total 
granules) (Erjefalt et al., 1998). 
2.2.6 Eosinophil purification 
Eosinophils from the peritoneal cavity of IL-5 Tg BALB/c mice and from the BALF of 
allergic WT mice were purified by FACS (fluorescence activated cell sorter; FACStar 
Plus, Becton Dickinson, San Jose, CA) according to their characteristic forward scatter 
(FSC) vs . side scatter (SSC) plot and light polarization properties as previously 
described (Mould et al. , 1997). The purity of the enriched population was approximately 
95% as determined by differential staining with Giemsa-May-Grunwald. Greater than 
98% of the purified eosinophils were deemed viable by trypan blue exclusion. 
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A Type I B Type II 
C Type Ill D Type IV 
FIGURE 2.1- Phenotypes of secondary granules from eosinophils. A, Type I 
granules are intact granules without loss of the crystal core nor the matrix; B, 
Type 11 granules have lost proteins associated with the crystal core; C, Type 111 
granules display loss within the matrix compartment; D, Type IV granules have 
lost constituents within both the crystal core and the matrix. 
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2.2. 7 Measurement of AHR 
Airways reactivity to methacholine was measured in conscious, unrestrained mice 
using a barometric plethysmograph (Buxco, Troy, NY) as previously described (Webb 
et al., 2000). 13riefly, mice were placed in a plethysmograph chamber and exposed to 
an aerosol of water to obtain baseline readings of enhanced pause (Penh). Mice were 
then exposed to cumulative concentrations of methacholine ranging from 3.1 to 50 
mg/ml. The aerosol was generated by an ultrasonic nebulizer and drawn through the 
chamber for 2 min. The inlet was then closed and Penh readings taken for a further 3 
min. Data were averaged and reported as the percentage increase in Penh over 
baseline. Penh values are only shown at the concentration which induced the maximal 
response but data are reflective of responses obtained with the full dose response 
curve. 
2.2.8 Adhesion Assay 
Eosinophil adhesion was monitored in triplicate samples by measuring eosinophil 
peroxidase content of adherent cells. The cells were cultured in 96-well flat-bottom 
tissue culture plates, which were coated with 2.5°/o bovine serum albumin (BSA) in PBS 
for 2 h at 37°C. The wells were rinsed three times with RPMl-1640. After purification, 
eosinophils were washed and resuspended in RPMl-1640 at a concentration of 5-
7.5x105 cells/ml. A 100 µI aliquot of the eosinophil suspension was added to each well. 
Stimulation of the eosinophils was initiated by the addition of an equal volume of the 
stimulus dissolved in RPMl-1640. The eosinophils were cultured for various periods of 
time at 37°C in a humidified atmosphere containing 5°/o CO2 . After the incubation, each 
well was gently washed three times with 200 µI of warm PBS to remove non-adherent 
cells . . EPO was extracted by lysing the eosinophils with 200 µI of 0.22%> 
cetyltrimethylammonium bromide (CTAB) dissolved in 10 mM HEPES buffer pH 8.0. 
Eosinophil adhesion was reported as a percentage of the EPO extracted from adherent 
cells according to the formula: 
o/o Adhesion = (EPO in adherent fraction/ Total EPO added to well) X 100 
The denominator was determined by measuring EPO content in an equivalent aliquot 
of cells added at the start of the experiment. The enzyme was extracted using 0.22%> 
CTAB dissolved in 10 mM HEPES buffer pH 8.0. The samples were frozen at -70°C 
until EPO content was measured using a colorimetric assay. 
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2.2.9 In vitro degranulation assay 
Eosinophils from the peritoneal cavity of IL-5 Tg mice, total BALF cells or purified BALF 
eosinophils from allergic WT mice were incubated in the presence of various stimuli to 
induce degranulation. The assay was performed in 24-well flat-bottom tissue culture 
plates that were coated with either a 2.5°/o BSA solution or a 1: 10 dilution of sera , 
isolated from control or allergic mice, for 2 h at 37°C. Approximately 5x105 cells were 
added to each well in a volume of 250 µI of RPMl-1640. An equal volume of culture 
media , which contained the stimulus , was added. The leukocytes were cultured for 0-4 
hours at 37°C in a humidified atmosphere containing 5°/o CO2. After incubation, the 
plates were centrifuged at 300 xg for 5 min. The supernatant was collected and stored 
at -70°C until assay for MBP. 
The morphology of cultured eosinophils was assessed by transmission electron 
microscopy. The cells were cultured as above, however, an insert, which was coated in 
succession with poly-L-lysine (10 mg/ml) and then BSA (2.5o/o w/v in PBS) was 
introduced into the well. The cells were stimulated for 3 h in the presence or absence 
of 10-7 M phorbol-12-myristate-13-acetate (PMA). After the incubation, the inserts were 
gently rinsed with warm PBS three times. The cells were fixed in 2°/o glutaraldehyde 
dissolved in 0.1 M sodium cacodylate buffer pH 7.4 at 4°C overnight. The subsequent 
steps were performed as described above. 
2.2.10 Detection of EPO and MBP 
EPO content in cell-free BALF and eosinophil lysates was measured using a 
colorometric assay (Bozeman et al. , 1990; Schneider and lssekutz, 1996). Briefly , a 75 
µI aliquot of sample was transferred to a 96-well microtiter plate and the reaction was 
initiated by the addition of 75 µI of substrate solution . (12 mM o-phenylene diamine, 
0.005°/c, H20 2 in 10 mM HEPES pH 8.0). CTAB is not only a detergent used to disrupt 
membranes but also serves as a source of bromine ions required by EPO. The final 
concentration of CT AB in the reaction was 0.11 °/o w/v and was present in the lysates or 
added to the substrate solution when analyzing BALF. The enzymatic reaction was 
stopped after a 30 min incubation at room temperature by the addition of 50 µI of 4 N 
H2S04. Absorbance at 490 nm was measured using a Thermomax microplate reader 
and data was analyzed using SoftMax (vers ion 2.01 ; Molecular Devices Corp , Melon 
Park, CA). 
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The presence of MBP in supernatants from cultured eosinophils was assessed using 
an immunodot blot assay, developed with Western Blue as previously described 
(Mould et al., 2000). 
2.2.11 Statistical analysis 
Data are presented as the mean + standard error of the mean (SEM) except for 
the data describing a frequency of occurrence in a sample population , which were 
presented as a percentage. Statistical significance of differences between experimental 
groups was assessed with Student's unpaired t test or Chi-Square analysis. 
Differences in means were considered significant if p < 0.05. 
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2.3 RESULTS 
2.3.1 Detection of eosinophil granule proteins in cell-free BALF of allergic 
mice 
The lungs of allergic -wr and -IL-5 Tg mice were characterized by the infiltration of 
eosinophils (Fig. 2.2A), the presence of EPO (Fig. 2.28) in cell-free BALF and the 
development of AHR in response to methacholine (Fig. 2.2C). The eosinophil was the 
predominant leukocyte present in BALF, representing 70°/o and 89°/o of BALF cells 
recovered from wr and Tg mice, respectively. A significant increase in the numbers of 
lymphocytes, macrophages and to a lesser degree neutrophils was also observed 
(results not shown). Notably , elevations in the concentrations of EPO in the BALF 
directly correlated with the development of both airways eosinophilia and AHR. 
Eosinophil numbers in the lung of IL-5 Tg mice were greater than that observed in wr 
mice, however, AHR and EPO levels were similar suggesting that these indices were at 
maximal levels of detection. These hallmark features of allergic inflammation also 
correlated with the induction of mucus hypersecretion as previously shown (Webb et 
al., 2000). 
2.3.2 Piecemeal degranulation is the principal mechanism for granule 
protein release from eosinophils in the allergic lung 
Electron microscopic analyses of eosinophils in the bone marrow, blood, airway tissue 
and BALF were undertaken to determine the extent of cellular activation and the 
mechanism(s) for granule protein release (Table 2.1 and Fig-. 2.3) . We observed a 
subpopulation of activated eosinophils in these four compartments in allergic mice 
(Table 2 .1 ). Furthermore, all activated eosinophils released granule proteins by 
piecemeal degranulation. Although some eosinophils from the bone marrow and blood 
of allergic mice displayed characteristics of piecemeal degranulation , it was normally 
confined to one or two granules per cell and these granules had lost only a small 
amount of either the core or matrix (Fig. 2.3A). However, once in the lungs, a greater 
proportion of eosinophils resident in tissues were activated and undergoing piecemeal 
degranulation (Table 2.1) but the degree of granule protein loss was moderate (Fig . 
2.38) . 
Although increased numbers of activated eosinophils were observed in allergic tissue , 
the vast majority of cells that were activated and undergoing degranulation were found 
in the BALF (Table 2.1 and Fig . 2.3). The migration of eosinoph ils into the airway 
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FIGURE 2.2- Detection of EPO in cell-free BALF directly correlates with the 
development of airways eosinophilia and AHR in the allergic lung. OVA 
sensitization and challenge of WT and IL-5 Tg mice induced hallmark features of 
allergic disease of the lung. A, Number of eosinophils in the airway lumen are 
reported as the mean total eosinophils isolated within BALF+ SEM (n= 5-8 mice per 
group). B, EPO concentration in cell-free BALF was determined using a standard 
colorometric assay. Data were individually collected from 6 mice per group, with 
each sample analyzed in duplicate. The results are presented as the mean optical 
density measured at 490 nm + SEM. C, Airways reactivity to methacholine 
(25mg/ml) was monitored by barometric plethysmography. The data are presented 
as the percent increase in Penh above baseline values (mean + SEM, n= 6-8 mice 
per group). * p < 0.01 when compared to saline-sensitized/ OVA-challenged group 
and t p < 0.05 when compared to WT mice after identical experimental treatments. 
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Table 2.1-Eosinophil morphology differs according to tissue compartment occupied. 
Genotype 
WT 
IL-5 Tg 
Eosinophil population 
Bone marrow 
Blood 
Tissue 
BALF 
Bone marrow 
Blood 
Tissue 
BALF 
0/o Resting 
82 
74 
64 
33 
77 
74 
60 
17 
Exocytosis 
0 
0 
0 
0 
0 
0 
0 
0 
o/o Degranulating 
PMD 
18 
24 
36 
63 
23 
26 
40 
83 
Cytolysis 
0 
0 
0 
0 
0 
0 
0 
0 
% Apoptotic 
0 
2 
0 
4 
0 
0 
0 
0 
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A B 
C D 
FIGURE 2.3- Electron photomicrogr-aphs of mouse eosinophils during allergic 
airways disease. Eosinophils present in the bone marrow or in the peripheral 
blood displayed few signs of activation. Only slight changes in the morphology 
of secondary granules were observed in bone marrow derived eosinophils 
(arrow and inset in A). While a greater proportion of eosinophils in pulmonary 
tissue were activated (morphological changes in granule structure), the cells in 
the submucosa released only modest quantities of granule proteins by piece-
meal degranulation (arrow depicts type Ill granule in 8). However, eosinophils 
in the airways lumen became highly activated with a concomitant release of 
granule proteins by piecemeal degranulation. In BALF eosinophils ( C), a large 
number of granules were type IV (balck arrow) and were surrounded by small 
vesicles (white arrow) . Macrophages in the airways lumen phagocytosed 
apoptotic bodies derived from eosinophils (arrow in 0). Data is representative 
of 2 samples taken from 6 mice each for bone marrow, blood and airway 
lumen eosinophils. For tissue-resident eosinophils, lung sections from 4 mice 
were analyzed. 
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correlated with a dramatic change in morphology. A large proportion of granules lost 
either the core, matrix or both granule constituents (Fig. 2.3C). Notably , the secondary 
granules in BALF eosinophils were surrounded by large numbers of small vesicles , 
which have presumably budded from these granules to facilitate the transport of 
proteins to the cell surface. These small vesicles were absent in eosinophils from all 
other compartments. The morphology of BALF eosinophils classically represented 
piecemeal degranulation. 
Only a small fraction of eosinophils in the airway lumen of allergic mice were apoptotic 
(Table 2.1 ). However, we often observed that macrophages in the airway lumen had 
engulfed eosinophil constituents including intact secondary granules (Fig. 2.30). 
2.3.3 Eosinophils in the airway lumen have the highest activation status 
Concurrently with morphological description of eosinophil degranulation, we attempted 
to quantify their activation status by grading the degree of degranulation per cell in a 
defined compartment relative to eosinophils isolated from naive (non allergic) mice 
(Fig. 2.4). Resting eosinophils contained only type I granules, while activated 
eosinophils possessed both intact granules and those displaying at least a partial loss 
of granule content (types II-IV). When the data was transformed into the degranulation 
index (on a scale of O to 100, where O indicates a resting eosinophil and 100 a fully 
activated cell with no type I granules) distinct differences in the degree of activation 
were observed between eosinophils residing in the various compartments (Fig. 2.4A). 
Eosinophils isolated from naive mice had a degranulation index equal to bone-marrow 
derived eosinophils from allergic mice. Furthermore, in the case of WT mice, the 
degranulation index of circulating eosinophils increased significantly after allergen 
provocation (9.9+ 1. 7 vs. 16.2 + 2.6, p<0.05). Although eosinophils in lung tissue of 
allergic mice were activated (in contrast to control and bone marrow-derived cells), the 
highest activation status was observed in the airways lumen. This is particularly evident 
after classifying the eosinophils as low, moderately or highly activated (Fig. 2.48) and 
when the proportion of type IV granules is compared between eosinophil populations in 
the various compartments (Fig. 2.4C). Movement from the tissue to the airway lumen 
significantly promoted the loss of both the crystal core and matrix from individual 
granules. These data directly correlate with the morphological assessment of 
eosinophil activation (Fig . 2.3 and degranulation index). Several differences were 
observed between WT and IL-5 Tg eosinophils in the various compartments of allergic 
mice. Notably, although the proportion of activated eosinophils in IL-5 Tg mice was 
only slightly increased within any one compartment (Table 2.1 ), those cells that 
0) 
""1'" 
FIGURE 2.4- Quantification of the activation status of eosinophils in different compartments of allergic mice. A, Changes in the 
degranulation index as eosinophils migrate to sites of allergen provocation. The degranulation index for each eosinophil was 
calculated using the formula presented in Materials and Methods. The data represent the mean degranulation index + SEM. 
Significant _differences between groups are indicated as *p < 0.05 or **p < 0.001. B, Proportion of eosinophil populations with low, 
moderate and high activation status. The cells were classified according to the degranulation index into low (0-20), moderately (20-
40) or highly (40-100) activated. C, Proportion of type IV granules in different eosinophil populations. The secondary granules were 
classified and counted as previously described (Erjefalt et al., 1998). The data are presented as the perc·entage of type IV granules. 
A minimum of 200 granules were counted for each sample. Significant differences (*p < 0.01) were determined using the Chi-square 
analysis. 
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became activated reached higher levels of activation (Fig . 2.4A, 8) . This difference was 
particularly evident in comparison of BALF populations. 
2.3.4 High thresholds for the activation of mouse eosinophils by PMA 
Since eosinophil degranulation in the lung of allergic mice was primarily 
compartmentalized to the airway lumen in contrast to the airways of atopics, we 
characterized the response of mouse eosinophils to PMA to determine whether 
significant differences exist in the regulation of human and mouse eosinophil activation. 
The activation of eosinophils by PMA was both time- and dose-dependent (Fig. 2.5-
2.6). The initial response to PMA stimulation was cellular adhesion to the extracellular 
matrix followed by degranulation (Fig. 2.5) . Eosinophil adhesion reached a maximum 
after approximately 60 to 90 minutes of stimulation, at which time MBP release was 
first observed. Subsequently, the secretion of MBP increased consistently until the 
experiment was terminated after 4 hours. Titration of PMA concentration determined 
that mouse eosinophil activation occurred at concentrations as low as 1 nM but only 
reached a maximum at 100 nM (Fig. 2.6). 
Since high concentrations of PMA were required to induce eosinophil degranulation, 
we characterized the ultrastructural morphology of the eosinophils to exclude . the 
possibility that cytotoxic effects of PMA were the cause of MBP secretion (Fig. 2. 7). 
Electron microscopic analysis of PMA-stimulated eosinophils confirmed that the cells 
were highly activated and revealed that piecemeal degranulation was the likely 
mechanism for MBP release (Fig. 2.78). In unstimulated cells, the secondary granules 
displayed no alterations as they contained an intact matrix surrounding an electron-
dense core (type I) (Fig. 2.7 A). This core is composed primarily of MBP (Denzler et al., 
2000). After stimulation, the release of MBP was accompanied by an increase in the 
number of secondary granules displaying a complete or partial loss of the core (type II) 
(Fig. 2.78, C). Accordingly, the degranulation index of eosinophils increased after 
stimulation with PMA (Fig. 2.70). These results directly correlate with the biochemical 
analysis of eosinophil activation and indicate that MBP release is not the by-product of 
cellular degenerative processes. 
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FIGURE 2.5- Kinetics of mouse eosinophil adhesion (A) and degranulation (B). 
Eosinophils were incubated in medium alone or stimulated with 100 nM PMA for 
the times indicated. A, After washing the wells, total EPO in the adherent cells was 
quantified. Adhesion is represented as the percentage of EPO activity added to 
each well at t = 0. The results are expressed as the mean + SEM of 3 separate 
experiments. Significant differences are *p < 0.01 and **p < 0.001 from values 
obtained without stimulus. B, Degranulation was monitored by release of MBP into 
the supernatant and was detected by immunodot blot. The results were scored as a 
(-) which indicates a background signal and a ( +) indicating the detection of MBP 
with the number of + signs being directly proportional to the color intensity of the 
dot. 
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FIGURE 2.6- The effect of PMA concentration on eosinophil adhesion (A) and 
degranulation (8). Eosinophils were stimulated for 90 min (A) or 4 h (B) with the 
indicated concentrations of PMA. A, After washing of the wells , total EPO in the 
adherent cells was determined. Adhesion is expressed as a percentage of EPO 
added per well at t = 0. The results are expressed as the mean + SEM of 3 separate 
experiments. Significant differences are *p < 0.02 and **p < 0.002 from values 
obtained without stimulus. B, Culture supernatants were recovered and MBP release 
was determined by immunodot blot. Results were scored as described in fig 2.5. 
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FIGURE 2.7- Electron microscopic analysis of PMA-stimulated eosinophils. A, Eosinophils incubated in medium alone show no or 
few signs of degranulation as the secondary granules display an intact electron dense core surrounded by matrix (type I granule; see 
arrows). B, However, PMA stimulated eosinophils undergo piecemeal degranulation. The secondary granules have an altered 
phenotype with partial or complete loss of the core but an intact matrix (type 11 ; see black arrow) or partial loss of both the core and 
matrix (type IV; see white arrow). C, Distribution of granule types in eosinophils after PMA stimulation . The secondary granules were 
counted and categorized in four groups according to granule morphology. The data are presented as the percentage of each granule 
type from the total secondary granules. Significant differences are *p < 0.001 when compared to unstimulated cells . 0 , Effect of PMA 
on degranulation index. The data is presented as the mean ± SEM. 
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2.3.5 Antigen induces eosinophil degranulation 
BALF cells were stimulated with anti-CD3 and OVA to determine if the activation of T 
cells in respiratory secretions could potentially trigger eosinophil degranulation . Purified 
eosinophils were also exposed to antigen to determine if antigen uptake or ligation to 
FcR- lg complexes could modulate eosinophil activation. PMA was used as a positive 
control for the induction of degranulation. MBP was released by eosinophils after 
activation by PMA and exposure to OVA but not by anti-CD3 stimulation. Furthermore, 
OVA interacted directly with eosinophils inducing degranulation in a highly purified 
eosinophil population (Table 2.2). 
Table 2.2- Eosinophils degranulate in response to antigen. 
Cell population Control PMA anti-CD3 OVA 
Total BALF cells - + - + 
BALF eosinophils - + N.D. + 
Cellular populations isolated from the airway lumen were cultured in the presence of 
vehicle control, 100 nM PMA, anti-CD3 or 100 µg of OVA for 4 to 6 h. The culture 
supernatant was recovered and MBP content was assessed using immunodot blot. 
The data is represented as a positive signal (+) or a background signal (-). N.D.= not 
determined. 
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2.4 DISCUSSION 
Mouse models of allergic airways disease have been extensively employed to identify 
the potential contribution of pulmonary eosinophilia to the pathogenesis of human 
asthma (Kumar and Foster, 2002) . Although many studies have linked eosinophil 
accumulation in affected tissues with the expression of disease (Foster et al., 1996; 
Hamelmann et al., 1999a; Tomkinson et al. , 2001 ), interpretation of the significance of 
these investigations has been limited by the failure to observe extensive activation and 
degranulation of eosinophils at sites of inflammation (a common feature of human 
allergic disorders) (Malm-Erjefalt et al., 2001 ; Stelts et al., 1998). In this investigation 
we show that eosinophils release granule proteins in the lung via piecemeal 
degranulation during allergic inflammation of the airways. However, by contrast to 
asthmatic airways (Erjefalt et al. , 1998; Erjefalt et al. , 1999), degranulation was 
primarily compartmentalized to the airway lumen. 
Migration of eosinophils into the airway lumen during allergic inflammation resulted in 
marked activation and the induction of piecemeal degranulation. The ultrastructural 
features, and in particular, the fraction of granules with a partial loss of both matrix and 
core (type IV granules) and the degranulation index, strongly indicated a significant 
loss of granule proteins into the airway lumen in response to antigen inhalation. 
Indeed , concomitant with ultrastructural changes, significant levels of non-cell-
associated EPO were detected in the BALF of allergic mice. Eosinophil recruitment in 
to the lungs and activation correlate with the induction of AHR supporting earlier 
studies with rats and primates that directly link eosinophils and their constituents with 
the induction of disease processes in the lung (Gundel et al., 1991; Uchida et al., 
1993). A recent report has also established a temporal-association between the 
release and persistence of EPO in the airway lumen with the induction and resolution 
of AHR (Tomkinson et al., 2001). However, it should be noted that AHR is not 
attenuated in the allergic lung of mice deficient in MBP or EPO, indicating that 
eosinophils may also regulate airways reactivity independently of these proteins or that 
other pathways may operate in parallel with granule-induced processes in the allergic 
lung (Denzler et al. , 2001 ; Denzler et al. , 2000). 
The release of granule proteins in BALF was not due to sample processing or the 
result of cellular degenerative processes , since the ultrastructural morphology of BALF 
eosinophils showed that degranulation occurred via an active process that was 
reproducibly confined to a distinct percentage of cells . lmmunohistochemical studies 
have also described the deposition of extracellular MBP on the apical surface of 
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epithelial cells during allergic inflammation of the lungs of mice exposed to ti/aria/ 
antigens, indicating that eosinophil degranulation occurs in vivo and not ex-vivo in the 
lavage fluid (Mehlotra et a/., 1998). Furthermore, recruitment of eosinophils to the 
airways of naive mice by the overexpression of IL-5 and eotaxin does not subsequently 
result in eosinophil degranulation in isolated BALF (Mould et a/., 2000). We also 
routinely isolate large numbers of eosinophils from body compartments (peritoneal 
cavity and blood of IL-5 Tg mice) and have not observed degranulation ex-vivo (Mould 
et al., 1997). 
Although eosinophils were activated in our model, both similarities and differences 
were observed between mouse and human eosinophils participating in allergic 
disease. In our mouse model, as in clinical studies, free granule proteins were 
observed in BALF (Fujimoto et al., 1997; Louis et al., 2000), allergen challenge 
increased the activation level of circulating eosinophils (Karawajczyk et al., 2000), 
piecemeal degranulation was the primary mechanism for granule decomposition 
(Erjefalt et al., 1998; Erjefalt et al., 1999) and apoptotic eosinophils were rare (Erjefalt 
et al., 1998; Erjefalt et al., 1999). By contrast to human studies (Bozza et al., 1997; 
Erjefalt et al., 1998; Erjefalt et al., 1999), eosinophils resident in the tissues of the 
allergic lung of mice displayed only a low level of activation, cytolytic eosinophils were 
not observed and lipid bodies were rare. These latter observations are in agreement 
with a previous study (Malm-Erjefalt et al., 2001; Stelts et al., 1998) and suggest that 
the mechanisms regulating degranulation of mouse and human eosinophils and/or the 
micro-environment within allergic tissues differs between these species. 
Molecules which prime eosinophils can also induce eosinophil degranulation but to a 
considerably lower degree (Fujisawa et al., 1990; Horie et al., 1996; Koenderman et 
a/., 1996). According to the criteria used in this study many of the eosinophils in the 
blood and tissues of allergic mice are primed and become further activated to 
degranulate in the airway lumen. Indeed, eosinophils chronically stimulated with IL-5 in 
IL-5 Tg mice possessed higher basal levels of activation and attained greater levels of 
activation after immune stimulation in the airway lumen. The compartmentalization of 
degranulation primarily to the lumen of the lung may reflect distinct spatial and 
temporal aspects of acute allergic responses, which are in marked contrast to chronic 
inflammation , which is observed in human asthma. 
In order to characterize the similarities and differences in the regulatory mechanisms of 
cellular activation between mouse and human eosinophils, we investigated the effect of 
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PMA on adhesion and degranulation processes. Our data indicate that several features 
of activation have been conserved between mouse and human eosinophils. Firstly, 
mouse eosinophils adhered and degranulated in a time- and dose-dependent manner 
in response -to PMA. Although the process of adhesion was slower with mouse 
eosinophils, like human cells, adhesion preceded degranulation. Thus, adhesion 
molecules may play a central role in the regulation of mouse eosinophil degranulation 
as is observed with human cells (Egesten et al., 1993; Horie and Kita, 1994; Kaneko et 
a/., 1995a). Interestingly, human and mouse eosinophils have similar adhesion 
molecule profiles with both species expressing LFA-1 (aLB2), Mac-1 (aMB2) and VLA-4 
(a4B1 ). These molecules have been implicated in the regulation of various cellular 
functions including cell-matrix and cell-cell contacts, migration and activation (Horie 
and Kita, 1994; Kaneko et al., 1995a; Mengelers et al., 1995; Nakajima et al., 1994; 
Rabb et al., 1994). Secondly, in response to PMA, mouse eosinophils released MBP 
by piecemeal degranulation, a process widely observed in human eosinophil 
populations both in vitro (in response to various stimuli including PMA) and in vivo 
(Dvorak, 1994; Dvorak et al., 1992; Dvorak et al., 1991; Erjefalt et al., 1998; Erjefalt et 
al., 1999; Malm-Erjefalt et al., 2001 ). Piecemeal degranulation provides a mechanism 
for the preferential release of granule proteins (Tomassini et al., 1991 ). In response to 
PMA, mouse eosinophils appear to release, preferentially, proteins associated with the 
core, notably MBP. After activation, the largest proportion of secondary granules 
progressed from type I to type II granules (fig. 2. 7). 
In addition to piecemeal degranulation, cell death contributes to the release of MBP. 
Prolonged exposure of eosinophils to PMA resulted in cellular death as depicted by the 
loss of plasma membrane integrity and clear spaces within the cells. Notably, cellular 
death was confined to the adherent population as the non-adherent eosinophils 
remained viable throughout the experiment according to the trypan blue exclusion 
assay. This result is in agreement with a previous report which examined the viability of 
human eosinophils in response to slgA- and lgG-coated beads (Weiler et al., 1996). 
Since cell adhesion is instrumental in the process of degranulation, only adherent cells 
secrete cytotoxic cationic proteins which once bound to the cell surface induce cell 
death. Another potential explanation is that cell adhesion serves as a signal to induce 
cytolysis and permit the cell to secrete large quantities of mediators rapidly. Finally, the 
high concentration of PMA used in these experiments induced the adhesion of mouse 
eosinophils. Thus, it is unlikely that the release of MBP by mouse eosinophils is a 
passive process due to cellular death but more likely to be the result of a highly 
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regulated process involving cell adhesion , piecemeal degranulation and culminating in 
cytolysis . 
Although , the kinetics of adhesion and degranulation and the mechanism for the 
release of granule contents (piecemeal degranulation) were similar to human cells , 
higher concentrations of PMA were required to induce these responses (Horie and 
Kita , 1994; Malm-Erjefalt et al., 2001; Reimert et al., 1998). The optimal concentration 
of PMA required to stimulate both adhesion and degranulation would appear to be 
significantly different between species. Mouse eosinophil activation occurred at 
concentrations as low as 1 nM but only reached a maximum at 100 nM. In contrast, 
human eosinophils only require 1.5 nM of PMA to secrete maximal amounts of granule 
proteins (Horie and Kita, 1994; Reimert et al., 1998). The threshold of responsiveness 
highlights an important difference between human and mouse eosinophils (Malm-
Erjefalt et al. , 2001 ). 
To determine a potential mechanism regulating mouse eosinophil activation in vivo, 
eosinophils were cultured in the presence of various stimuli. Eosinophils can sequester 
antigen in the allergic lung and activate Th2 cells. We therefore investigated the 
possibility that factors associated with these processes promote degranulation 
(MacKenzie et al., 2001; Mattes et al., 2002; Shi et al., 2000). Th2 cell factors in 
association with cognate antigen have also implicated in regulating eosinophil 
degranulation in response to Nippostrongylus brasiliensis infection in mice (Shinkai et 
al. , 2002) . We were particularly interested in the effect of OVA as a potential 
secretagogue of airway eosinophils because it is not only a prominent molecule in the 
airway lumen in this experimental model but also because antigens activate 
eosinophils recovered from atopic patients (Kaneko et al. , 1995b; MacKenzie et al. , 
2001 ; Tomassini et al., 1991). The activation of T cells by anti-CD3 in cultured 
unfractionated BALF cells from allergic mice did not trigger eosinophil degranulation. 
However, incubation of both unfractionated BALF cells or purified eosinophils with OVA 
led to the release of MBP. The induction of degranulation by antigen is thought to occur 
by the binding to cytophilic immunoglobulins at the surface of the cell (Kaneko et al., 
1995b; Tomassini et al., 1991 ). Thus , the release of granule proteins in the airway 
lumen of allergic mice may be achieved through the interaction between Fe receptors , 
immunoglobulins and OVA at the surface of eosinophils . Interestingly , eosinophils 
recruited to the lung by the local expression of exogenous IL-5 and eotaxin in naive 
mice could only induce AHR after the concomitant delivery of OVA to the airways and 
this was coincident with the induction of MBP release from eosinophils (Mould et al. , 
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2000). Antigen is primarily localized to the airway lumen during acute inflammatory 
reactions in mouse models (MacKenzie et al. , 2001) and it is tempting to speculate that 
this phenomena results in eosinophil degranulation occurring primarily in this 
compartment .--The dose and dispersal of antigen within the lung may be an important 
determinants of where and if further eosinophil degranulation occurs in mouse models 
of allergic lung disease. Indeed, in studies where eosinophil degranulation was not 
observed in the allergic lung of mice only modest levels of antigen were delivered to 
the lung, with at markedly reduced exposure times by comparison to our investigation 
(Malm-Erjefalt et al., 2001; Stelts et al., 1998). 
In summary, we have provided evidence for eosinophil degranulation in our model of 
allergic airways disease and linked eosinophil activation in the airway lumen to the 
induction of AHR. EPO was detected in the BALF of sensitized mice and electron 
microscopy of eosinophils depicted morphological changes characteristic of piecemeal 
degranulation. Although the eosinophils in the airway submucosa were not releasing 
large amounts of granule contents, these cells were activated by comparison to control 
and bone marrow-derived eosinophils. However, eosinophils were highly activated in 
the airway lumen. Our in vitro studies indicate that like human cells, mouse eosinophil 
activation follows adhesion, but these cells are more resistant to activation by PMA. 
The differences (degree and site of activation) observed in vivo may be due, in part, to 
the higher thresholds for activation of mouse eosinophils and the acute nature of the 
disease process in mice compared to humans. Understanding the mechanisms 
regulating mouse eosinophil degranulation will help improve our interpretation of 
mouse models of allergic airways disease and enhance their value as correlates of 
human disease. 
Purification of eosinophils from bone marrow, 
blood and BALF of allergic mice using light 
polarization properties of cells 
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3.1 INTRODUCTION 
Several signals are required to cooperate in order for eosinophils to influence the 
pathogenesis of allergic diseases. In particular, IL-3, IL-5 and GM-CSF direct the 
proliferation and differentiation of eosinophils in the bone marrow (Lopez et al. , 1987; 
Mayer et al., 1989; Metcalf et al., 1986; Sanderson et al., 1985), the eotaxin family 
serves as the primary chemotactic signals within tissues (Forssmann et al., 1997; Jose 
et al., 1994; Kitaura et al. , 1999; Shinkai et al. , 1999) and immunoglobulins , lipid 
mediators and complement proteins activate eosinophils (Abu-Ghazaleh et al. , 1989; 
Horie et al., 1996; Kaneko et al., 1995b; Khalife et al., 1986; Khalife et al. , 1985; 
Kroegel et al. , 1989; Takafuji et al., 1994). These signaling networks lead to the 
release of pro-inflammatory mediators by eosinophils which modulate the inflammatory 
response and tissue function (Gundel et al., 1991; Hisamatsu et al., 1990). The 
temporal and spatial regulation of these signaling molecules produces eosinophil 
populations with different phenotypes. Indeed, in the previous Chapter, it was 
demonstrated that the activation status of eosinophils increases as the cells migrate to 
sites of inflammation. The ability to isolate eosinophils from the bone marrow, blood 
and BALF of allergic mice would permit the complete characterization of each 
eosinophil population and provide a platform to identify molecules which regulate the 
differentiation, migration and activation of eosinophils. The information may enable the 
discovery of new therapies to prevent eosinophil recruitment and activation within 
allergic diseases. 
Several methods currently exist to isolate specific eosinophil populations from humans 
and other species. These protocols were analyzed to determine whether they could be 
adapted to the purification of eosinophils from the bone marrow, blood and BALF of 
allergic mice. Firstly, eosinophils from human blood may be purified by either FACS or 
using immunomagnetic beads on the basis of CD16 negativity (Gopinath and Nutman, 
1997; Hansel et al., 1991 b; Thurau et al., 1996). In the first step, lymphocytes and 
monocytes are separated from the granulocytes by means of a density gradient. 
Subsequently, neutrophils can be distinguished from eosinophils due to the differential 
surface-expression of CD16 in myeloid cells. These methods are rapid and use a 
negative selection procedure minimizing effects on eosinophils. Unfortunately, a similar 
method could not be adapted for the isolation of mouse eosinophils because CD16 is 
constitutively expressed on the surface of mouse eosinophils (de Andres et al., 1994) 
and the current antibodies commercially available against mouse FcyR recognize both 
CD16 and CD32 (Serrander et al. , 2000). The latter molecule is widely expressed in 
eosinophils ( de Andres et al., 1994; Kim et al. , 1999). 
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Recently, methods have been developed to purify eosinophils from mice. Shinawaga 
and Anderson (Shinagawa and Anderson, 2000) have described a purification method 
of mouse eosinophils using immunomagnetic beads coated with antibodies directed 
against CD4 and CD8 present on lymphocytes, and lectins which preferentially bind to 
macrophages. However, this method is restricted to eosinophils isolated from the 
airway lumen of allergic mice. It might be difficult to convert this method for the isolation 
of eosinophils from the bone marrow and blood because, in contrast to BALF, these 
samples possess high levels of neutrophils requiring a method to distinguish and 
separate the two cell populations. Other researchers have described an alternative 
immunomagnetic method for the isolation of eosinophils from the spleen and blood of 
IL-5 Tg mice (Rothenberg et al., 1995; Teixeira et al., 1997). However, these methods 
do not separate the two granulocyte populations and rely primarily on the altered 
neutrophil to eosinophil ratio in the IL-5 Tg mice to overcome the problem. Hence, the 
primary hurdle to adapt any purification method to eosinophils present in different 
compartments of allergic mice is the ability to differentiate the granulocyte populations. 
While CD16 cannot be used as a marker to differentiate murine granulocytes as in the 
case of human cells, other surface markers could be used to distinguish mouse 
eosinophils from neutrophils. Thurau and colleagues (Thurau et al., 1996) successfully 
adapted CD49d expression for this purpose. Additional markers include C-C 
chemokine receptor (CCR)-3 and I L-5Ra. However, methods based on these 
molecules would involve a positive selection of eosinophils and ligation of these 
receptors with an antibody may activate intracellular signaling pathways. In order to 
recover eosinophils which represent as closely as possible the in vivo status of the 
cells, a negative selection process is required. 
Mouse eosinophils can also be purified from a complex mixture of cells by FACS using 
FSC vs. SSC and light polarization properties of cells as parameters (Mould et al., 
1997). Light polarization reflects the complexity of a cell including the granule content. 
Since the composition of granules is different between granulocyte populations, the 
cells might polarize light differentially permitting the distinction of each leukocyte. 
In this chapter, we determined whether light polarization was an adequate parameter to 
distinguish each leukocyte population including granulocytes. Indeed, eosinophils could 
be isolated from the bone marrow, blood and BALF of allergic mice using the FACS-
based method. Furthermore, preliminary investigations demonstrated the potential of 
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DNA micro-arrays and subtractive cloning in the identification of differentially expressed 
genes from eosinophils isolated from difference compartments. Cytokines and their 
receptors, chemokine receptors and cytotoxic cationic proteins were differentially 
expressed in bone marrow and BALF eosinophils. 
3.2 MATERIALS AND METHODS 
3.2.1 Animals 
See section 22.1 
3.2.2 Induction of allergic airways disease 
See section 2.2.2 
3.2.3 Collection of bone marrow, blood and BALF cells 
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Eosinophils were purified from the cellular populations present in the bone marrow, 
peripheral blood and BALF. The blood was collected from the femur artery of an 
anesthetized mouse into a tube containing heparin in PBS. The bone marrow cells 
were obtained from the femur by cutting each extremity of the bone and rinsing the 
cavity twice with 1 ml of PBS. The eosinophils present in the lumen of the airways were 
recovered by instilling in the lungs, via a catheter, 750 µI of PBS thrice. The samples 
. from several animals were pooled to ensure a sufficient number of cells was available 
for purification. 
3.2.4 Sample preparation for FACS analysis 
The red blood cells from all fractions were lysed using an ammonium chloride solution 
(0.16 M NH4CI, 0.17 M Tris pH 7.2). The cells were resuspended in PBS containing 1 °/o 
fetal calf serum (CSL Ltd., Parkville, Australia) and debris was removed by passing the 
suspension through FACS gauze. 
3.2.5 Purification of eosinophils by FACS 
Eosinophil purification was performed using a FACStar Plus instrument equipped with 
a 488 nm Coherent lnnova 90 laser (200 mW). Forward angle, 90° light scattering and 
light polarization were measured. For the latter, a filter set was installed into the FL 1 
(Polarizer-P-horizontal) and FL2 (Polarizer-S-vertical) channels. Eosinophils were 
selected using specific electronic gates and collected in PBS containing 5% fetal calf 
serum. The purity of the population was assessed by light microscopy after staining 
cytospins with either May-Grunwald-Giemsa dyes. 
3.2.6 May-Grunwald-Giemsa staining of cells 
Purified cells were cytospun onto glass slides, air dried and fixed in ethanol for 15 min 
prior to staining. Subsequently, the samples were successively stained for 5 min in 
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May-Grunwald solution (0 .15 °/o May-Grunwald, 50% methanol dissolved in a 
commercial buffer (buffer tablets pH 6.4 for staining of blood smears according to the 
Weise protocol, BDH Lab Supplies, Poole, England)) and 10 min in Giemsa stain 
(0.125°/o Giemsa, 7.25°/o glycerol, 8.3°/o methanol dissolved in the Weise buffer). To 
wash away the excess stain, cells were destained in Weise buffer for 10 min. The 
specimens were air dried and mounted for visualization by light microscopy. 
3.2. 7 Adhesion assay 
See section 2.2.9 
3.2.8 Degranulation assay 
See section 2.2.10 
3.2.9 EPO assay 
See section 2.2.11 
3.2.10 MBP dot blot 
See section 2.2.11 
3.2.11 Purification of RNA 
Total RNA was extracted from the purified eosinophils using a one-step solution based 
on a method devised by Chomczynski et al. (Chomczynski and Sacchi, 1987). The 
cells were lysed in RNAzol™ B (Geneworks Pty. Ltd., Adelaide, SA, Australia) at 
2.5x106/ml. After the first phenol-chloroform extraction, the aqueous phase was mixed 
with an equal volume of RNAzol™ B and 115th volume of chloroform. The RNA was 
finally recovered by precipitation using GlycoBlue TM (Ambion Inc., Texas, USA) as 
carrier at a concentration of 30-50 µg/ml and an equal volume of isopropanol. The RNA 
pellet was washed once with 75°/o ethanol before being dissolved in diethyl 
pyrocarbonate (DEPC)-water. The RNA was quantitated by spectrophotometric 
analysis whereby the absorbance at 260 nm was measured. 
3.2.12 RNA gel electrophoresis 
RNA samples were separated by gel electrophoresis using a 1.2°/o agarose gel 
prepared in 1X FA buffer (20 mM 3-[N-morpholino]propanesulfonic acid , 5 mM sodium 
acetate, 1 mM EDTA pH 7.0) supplemented with 0.7°/o formaldehyde and 0.1 µg/ml 
ethidium bromide. The gel was equilibrated in running buffer (1X FA buffer, 0.7°/o 
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formaldehyde) for 30 min. RNA samples (1-2 µg) were diluted with 0.2 volumes of 
loading buffer (4X FA buffer, 2.7°/o formaldehyde, 20°/o glycerol, 31 °/o formamide, 
0.25°/o bromphenol blue), heated to 65°C for 3-5 min and subsequently chilled on ice. 
The entire sample was loaded onto the gel. A constant voltage of 100 V was applied 
during the electrophoresis procedure. 
3.2.13 RT-PCR 
The first-strand complementary (c)DNA synthesis was performed using the SMART 
technology developed by ClonTech Laboratories (Palo Alto, CA, USA). Total RNA (1 
µg) was reverse transcribed according to the manufacturer's protocols. The RNase H-
reverse transcriptase Superscript™ II (Gibco BRL, Mulgrave, Vic, Australia) was 
employed in all reactions. 
Polymerase chain reaction (PCR) amplification of specific genes was performed 
according to standard protocols (Ausubel et al., 1998). The sequence of all gene-
specific primers are defined in Table 3.1. The cDNA was amplified using an initial 
denaturation step of 2 minutes at 95°C followed by 20 to 35 cycles of 15 seconds at 
95°C, 15 seconds at 50°C and 90 seconds at 72°C. A final extension at 72°C was 
performed for 7 minutes. The PCR products were separated by electrophoresis in a 2%> 
agarose gel and visualized using either ethidium bromide or Vistra TM Green (1: 10000; 
Amersham Pharmacia Biotech Pty. Ltd., Sydney, NSW, Australia) as fluorescent 
marker. The image of the gel was recorded using a Fluorescent Image Analyser FLA-
3000 (Fuji Film, Japan) and analyzed with lmagegauge 3.11 software. The intensity of 
the cDNA bands were normalized to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). 
69 
Table 3.1- Sequence of gene-specific primers utilized for expression profiling of 
eosinophils. -
Primer Sequence 
GAPDH, sence 5' ACC ACA GTC CAT GCC ATC AC 3 ' 
GAPDH, anti-sense 5' TCC ACC ACC CTG TTG CTG TA 3 ' 
IL-4, sense 5' GAA TGT ACC AGG AGC CAT ATC 3 ' 
IL-4, anti-sense 5; CTC AGT ACT ACG AGT AAT CCA 3 ' 
IL-5, sense 5' GAC AAG CAA TGA GAC ACG ATG AGG 3 ' 
I L-5 anti-sense 5' GAA CTC TGC AGG TAA TCC AGG 3 ' 
IL-12, sense 5' CGT GCT CAT GGC TGG TGC AAA G 3 ' 
IL-12, anti-sense 5' CTT CAT CTG CAA GTT CTT GGG C 3 ' 
IL-13, sense 5' CTC CCT CTG ACC CTT AAG GAG 3 ' 
IL-13,anti-sense 5' GAA GGG GCC GTG GCG AAA CAG 3 ' 
IFN-y, sense 5' AAC GCT ACA CAC TGC ATC TTG G 3 ' 
I FN-y, anti-sense 5' GAC TTC AAA GAG TCT GAG G 3' 
CCR-3, sense 5' AAG TAC AGG AAG CTA CAA ATT ATG 3 ' 
CCR-3, anti-sense 5' AGC AGA GTT TTA ATG ATT CCT GAG 3 ' 
CCR-4, sense 5' ATC GTG CAC GCG GTA TTC TCC 3 ' 
CCR-4, anti-sense 5' GAC GGG GTT AAG GCA GCA GTG A 3 ' 
CxCR-3, sense 5' TCA TCT TCC TGT CAG CCA GC 3 ' 
CxCR-3, anti-sense 5' CAC CAC CAC CAC CAC CAC TA 3 ' 
MBP, sense 5' AAG GAA GAA GGT TCT GGA AGT GA 3 ' 
MBP, anti-sense 5' CCA GTA TGC AAA ATT CCA AGA ACT 3 ' 
IL-5Ra, sense 5 / ATT AAA GCC ACT GGA TTA GCT CAA 3 I 
IL-5Ra, anti-sense 5' ATT GCT TTC AAT TTC CAC TGT GAC 3 I 
IL-4Ra, sense 5' GCC CCA GTG GTA ATG TGA AGC CCC 3 ' 
IL-4Ra, anti-sense 5' CCC AGA GGG GCA CCT GTG CAT cc 3' 
IL-13Ra1, sense 5' ACA GAA GTT CAG CCA CCT GTG ACG 3 ' 
IL-13Ra1 , anti-sense 5' GGT GGA GTT TTG CTC CTT ACC TAT AC 3 ' 
IL-13Ra2, sense 5' ATG GCT TTT GTG CAT ATC AGA TGC 3 ' 
IL-13Ra2, anti-sense 5' GGT GTG CTC CAT TTC ATT CTA ATA TC 3 ' 
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3.3 RESULTS 
3.3.1 Eosinophilia reached maximal levels on day 31 
The kinetics for the development of an eosinophilia in the bone marrow, peripheral 
blood and BALF within the mouse model of allergic airways disease were measured in 
order to possess optimal cell numbers for purification purposes. Eosinophil numbers in 
all compartments increased slightly after each of the first 3 challenges. However, the 
exposure of mice to antigen on day 30 led to a sharp increase in eosinophilia in all 
compartments (Fig. 3.1 ). Additional exposures of the mice to OVA either led to a 
decrease in eosinophil levels or only minor increases. Hence, cellular populations 
isolated from the bone marrow, blood and BALF of allergic mice on day 31 were 
utilized for the isolation of eosinophils. 
3.3.2 Amplification of a cell population with high side scatter and light 
polarization properties during allergy 
During allergic airways disease, the presence of lymphocytes, neutrophils and 
monocytes/macrophages also increased in the different compartments ( data not 
shown). However, only the eosinophil population displayed a marked increase as a 
fraction of the entire leukocyte population (Fig. 3.2). This effect was also very 
pronounced. In particular, while eosinophils only consisted of less than 1 °/o of all 
leukocytes in the BALF under normal conditions, the fraction of eosinophils increased 
to approximately 70o/o after antigen challenge. Hence, by comparing the profile of 
leukocyte populations on FACS under normal and allergic conditions, it may be 
possible to identify the eosinophils. 
Purification of eosinophil populations on the basis of the FSC vs. SSC plot and light 
polarization properties had previously been described (Mould et al., 1997). Gates for 
the purification of eosinophils by FACS using FSC vs. SSC and light polarization were 
set for the BALF population since eosinophils are the predominant leukocyte (70°/o) 
and granulocyte (>90°/o). In both the FSC vs. SSC and light polarization plots, a distinct 
population corresponding to the eosinophil was identified (Fig. 3.3-3.5). Unfortunately, 
these gates could not be directly used for the isolation of eosinophils from the bone 
marrow and blood because neutrophils have a similar profile to eosinophils. To 
distinguish the two populations, plots obtained from normal mice were compared to 
allergic mice. In both the bone marrow and blood samples, an increase was observed 
in a population displaying high SSC and light polarization properties (Fig. 3.3- 3.4) and 
71 
FIGURE 3.1- Kinetics for the generation of an eosinophilia in the bone marrow, blood 
and BALF during a murine model of allergic airways disease. BALB/c mice were 
sensitized to OVA and subsequently, challenged with antigen . The eosinophilia in 
each compartment was determined 24 hours after antigen exposure. A, Bone marrow 
eosinophilia. Since both eosinophil progenitors and mature cells are present in the 
bone marrow, all eosin positive cells were included in the sample. The data is 
presented as the average eosin positive cells/ femur+ SEM (n = 4-8 mice per group). 
B, Eosinophils in the peripheral blood. The data is expressed as the percentage of 
eosinophils in the blood (mean + SEM, n = 4-8 mice per group). C, Pulmonary 
eosinophilia. The data is presented as the total number of eosinophils in BALF (mean 
+ SEM, n = 4-8 mice per group). Significant differences are *p < 0.05 and **p < 0.001 . 
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FIGURE 3.2- The eosinophil is the only leukocyte population depicting an increase 
as a proportion of all leukocytes. The data is presented as the percentage of each 
leukocyte among the total cellular populations in bone marrow (A), peripheral blood 
(B) and BALF (C) (mean + SEM, n = 4-8 mice per group). For clarity, only the data 
collected before antigen challenge (day 23) and after the development of a strong 
inflammatory response (day 31) is presented . 
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FIGURE 3.3- A leukocyte population with a high side scatter is amplified during 
allergy. Cells were isolated from bone marrow and blood of control mice and bone 
marrow, blood and BALF of allergic mice. The FSC vs. SSC profile of each 
population was analyzed by FACS. Analysis of BALF (A) was used as an initial 
indicator since BALF consists of 70°/o eosinophils. In the bone marrow (B, control ; 
C, allergic) and blood (D, control; E, allergic), a population with a higher SSC, 
indicated by the arrow, is amplified during allergy. 
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FIGURE 3.4- A leukocyte population capable of polarizing light is amplified during 
allergy. Cells were isolated from bone marrow and blood of control mice and bone 
marrow, blood and BALF of allergic mice. A filter set which permits the measurement 
of light polarization was introduced in the channels FL-1 and FL-2 of the FACS 
instrument. Light polarization by each population was recorded. Analysis of BALF (A) 
was used as an initial indicator since BALF consists of 70°/o eosinophils. In the bone 
marrow (B, control; C, allergic) and blood (D, control; E, allergic) , a population which 
polarizes light, indicated by the arrow, is amplified during allergy. 
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FIGURE 3.5- Eosinophils are the leukocyte population with high side scatter and 
light polarization properties. Cells were purified by FACS using the selection 
criteria established in previous experiments (see Fig. 3.3 and Fig. 3.4). To identify 
the leukocyte population, the purified cells were cytopsun on glass slides and 
stained using the May-Grunwald-Giemsa stain as described in Materials and 
Methods (section 3.2.6). 
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corresponded to eosinoph ils (Fig . 3.5). Hence, by narrowing the gates established 
using the BALF sample , eosinophils from the bone marrow and blood could be 
obtained with very high purity (> 96%, ; see Table 3.2) . 
3.3.3 Eosinophil populations isolated by FACS were highly pure, viable 
and responded to exogenous stimuli 
The quality of the purification process was assessed by monitoring the viability of 
eosinophils using the trypan blue exclusion assay, differential counts of cytospins and 
response of eosinophils to PMA. Eosinophils isolated by FACS had a purity in excess 
of 96°/o and the viability within these populations was also very high (>95°/o) (Table 
3.2). The predominant leukocyte contaminating the eosinophil population was the 
neutrophil (Table 3.2). Unfortunately, the yield was significantly affected in the bone 
marrow and blood samples since the gates had to be carefully selected to exclude as 
many neutrophils as possible. 
In the previous Chapter, it was demonstrated that eosinophils in the BALF were highly 
activated and a small fraction were undergoing apoptosis. Thus, although the cells are 
viable according to the trypan blue exclusion assay, the cells may be no longer 
responsive and/or at early stages of cell death. Since it was established that 
eosinophils originating from IL-5 Tg mice respond to PMA (Chapter 2), BALF 
eosinophils were assessed for similar properties. Notably , BALF eosinophils adhered 
and degranulated after stimulation with PMA (Fig. 3.6). 
3.3.4 Purification of total RNA from mouse eosinophils 
Since the objective of these experiments was to identify differentially expressed genes 
within eosinophils as the cells migrate to sites of allergic disease, intact RNA must be 
isolated to prevent artefactual results. Hence, all RNA samples were subjected to gel 
electrophoresis to determine the quality of the material. The traditional one-step 
solutions permitted the extraction of good quality RNA from total bone marrow, blood 
and BALF cells. Furthermore, total RNA could be isolated from cells after a 6 hour 
incubation on ice (the time required for the purification of eosinophils ; Fig . 3.7) . 
Unfortunately , the RNA isolated from purified eosinophils was degraded. Several 
modifications to the extraction protocol were attempted to improve the quality of the 
RNA sample . By performing a second extraction , the quality of the transcripts was 
improved (Fig. 3.8). However, purification of cells directly into the one-step solution , 
~ 
CX) 
Table 3.2- Efficiency of purification method. 
Source Purity Contaminants o/o yield Viability % mature eos. 
Bone Marrow > 96°/o neutrophils/ - 20°/o > 95°/o - 75°/o 
lymphoid progenitors 
Blood > 97°/o neutrophils - 10-20°/o > 95°/o 100°/o 
BALF > 98o/o macrophages - 50°/o > 95°/o 100°/o 
Cells from the bone marrow, blood and BALF of allergic mice were isolated using standard 
techniques. Subsequently, red blood cells were lysed in an ammonium chloride solution and the 
leukocytes were resuspended in PBS containing 1 °/o fetal calf serum. Eosinophils were purified 
from each sample by FACS using the high SSC and light polarization properties of this leukocyte 
population. 
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FIGURE 3.6- Purified eosinophils were activated upon PMA stimulation. Eosinophils 
isolated from BALF were cultured in the presence of 10-7 M PMA or vehicle control as 
described in the Materials and Methods. A. Cell adhesion . At each time point, the 
wells were washed with warm PBS and adherent cells were lysed with a 0.22°/o CTAB 
solution . A colorometric assay was employed to quantify the levels of EPO in each 
fraction. The data is presented as the average 00490 units+ SEM from three samples. 
Significant differences are *p < 0.05. B. Degranulation. After a 4 h period of 
stimulation, the supernatant was recovered and extracellular MBP was detected using 
an immunodot blot. A representative blot from 3 experiments is presented. 
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FIGURE 3.7- Extraction of intact RNA from total cellular populations in the bone 
marrow, blood and BALF. Cells were isolated from the bone marrow, blood and 
BALF as described in the Materials and Methods. Subsequently, the cells were 
either lysed immediately or incubated on ice for 6 hours before lysis in RNAzol B. 
RNA was extracted from total cellular populations or purified eosinophils using 
RNAzol B according to the manufacturers' protocol. Approximately 1-2 µg of RNA 
from each sample was loaded onto a 1.2°10 formaldehyde-agarose gel, stained with 
ethidium bromide and visualized using a UV transilluminator. 
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FIGURE 3.8- Optimization of RNA extraction from eosinophils. RNA was extracted 
from total bone marrow or BALF cellular populations, or purified eosinophils using 
RNAzol B. The extraction procedure was performed twice as described in the 
Materials and Methods. Approximately 1-2 µg of RNA from each sample was loaded 
onto a 1.2°10 formaldehyde-agarose gel, stained with ethidium bromide and 
visualized using a UV transilluminator. 
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purification of cells over a short period of time, treating cells with RNAlatter™ or 
isolation of cells from IL-5 Tg mice did not improve the quality of the RNA. 
3.3.5 Amplification of genes from eosinophil RNA 
Since RNA which depicts a 2: 1 ratio of the 28S/18S bands by gel electrophoresis could 
not be isolated from eosinophils, it might be a consequence of the large quantities of 
ribonucleases in the cell. However, the RNA may still be useful in studying differentially 
expressed genes. To further characterize the RNA samples, reverse transcriptase 
(RT)-PCR was performed using RNA isolated from total BALF cells and purified 
eosinophils. In both circumstances, transcripts predominantly expressed by eosinophils 
including MBP, CCR-3 and IL-5Ra could be amplified (Fig. 3.9) . The results suggest 
that a fraction of the RNA remains intact but does not exclude the possibility that the 
quality of the RNA varies significantly from batch to batch or between different 
eosinophil . populations. A semi-quantitative approach was performed to assess this 
latter possibility. GAPDH was amplified from control RNA, RNA isolated from bone 
marrow eosinophils and BALF eosinophils . Although significantly less GAPDH 
transcript was present in the eosinophil RNA samples compared to the control RNA, 
the levels of GAPDH were equal between all eosinophil-derived samples (Fig. 3.10). 
Thus, the RNA degradation is consistent between samples or the RNA profile obtained 
by gel electrophoresis represents the actual RNA content of eosinophils. 
3.3.6 Several genes are differentially expressed between bone marrow and 
BALF eosinophils 
After extracting RNA from bone marrow and BALF eosinophils , semi-quantitative RT-
PCR was employed to identify if certain genes were differentially expressed in these 
cell populations. The RNA quality was verified by amplifying GAPDH and the levels of 
all other transcripts were normalized against GAPDH. Mouse eosinophils express 
cytokines and their receptors , chemokine receptors and cationic proteins. The 
transcription of these genes was greater in the BALF population except for MBP which 
was highly expressed in differentiating eosinophils (Fig. 3.11 ). Interestingly, IL-13 , the 
IL-4Ra and IL-13Ra 1 subunits were highly expressed in BALF eosinophils. 
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FIGURE 3.9- Genes predominantly expressed by eosinophils can be amplified by RT-
PCR. RNA (1 µg) extracted from total BALF cells and purified eosinophils was 
subjected to first-strand cDNA synthesis followed by 35 cycles of PCR amplification. 
The PCR products were resolved on a 1 °/o agarose gel, stained with ethidium bromide 
and visualized using a UV transilluminator. 
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FIGURE 3.10- GAPDH levels are equal between bone marrow and BALF 
eosinophils. First-strand cDNA was generated from 1 µg of total RNA. Subsequently, 
GAPDH was specifically amplified by PCR. The amount of PCR product was 
analyzed on a 1 °/o agarose gel after 20, 25, 30 and 35 cycles. A representative 
image of the PCR products after 25 cycles is presented. 
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FIGURE 3.11- Cytokines, cytokine and chemokine receptors and granule proteins are differentially regulated between bone marrow and 
BALF eosinophils. Total RNA was extracted from purified eosinophils from the bone marrow and BALF. Subsequently, 1 µg of RNA was 
subjected to RT-PCR using gene specific primers. The PCR products were separated on a 2°/o agarose gel and visualized using SYBR 
green. The signal intensity was measured using a Fluorescent Image Analyser FLA-3000. The data is reported as the ratio of fluorescence 
intensities of specific genes and GAPDH. 
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3.4 DISCUSSION 
Mouse models of allergic airways disease, in combination with the use of genetically 
modified mice, has allowed the dissection of signals regulating the differentiation and 
recruitmenf of eosinophils during inflammation. However, a more detailed analysis of 
the mechanisms regulating eosinophil functions has been hampered by the lack of 
adequate methods to purify different eosinophil populations. In this Chapter, the high 
SSC and light polarization properties of eosinophils were utilized to develop a FACS-
based purification method. The procedure permitted the purification of eosinophils 
resident in the bone marrow, blood and airway lumen of allergic mice. Furthermore, the 
cells were viable and responded to stimuli. This method may serve as a powerful tool 
to further study eosinophil biology in collaboration with the mouse models of asthma. 
The FAGS-based method overcomes the primary limitation of the other mouse 
eosinophil purification procedures, which is the lack of a marker to distinguish 
granulocytes. Light polarization properties of cells is an adequate criteria to 
differentiate each leukocyte population including granulocytes. Neutrophils polarize 
light significantly less than eosinophils. The difference may be attributable to the crystal 
core present in the secondary granules of eosinophils. Unfortunately, the neutrophil 
and eosinophil populations slightly overlap on FSC vs. SSC and light polarization plots. 
To discriminate between the two leukocytes, it is necessary to select narrow gates 
which allow for the selection of a specific cell type. While this strategy results in highly 
pure samples (> 96°/o), low yields are obtained. Another potential disadvantage may 
arise from this process as the purified population may not represent the diverse 
phenotypes of eosinophils in the original sample but be a sub-population . Hence, 
additional experiments aimed at the identification of other selection markers to 
distinguish granulocytes could improve the yield provided by this purification method . 
During the preparation of this manuscript, another method has been described for the 
purification of mouse eosinophils from the blood of I L-5 Tg mice (Borchers et al. , 2002; 
Shen et al. , 2003). The procedure involves the separation of the cells first by a density 
gradient followed by the depletion of T- and B-cells using immunomagnetic beads. This 
method permits the isolation of 5x108 eosinophils from 2 ml of blood . This method may 
provide an alternative to the FAGS-based purification procedure . However, the density 
of eosinophils is dependent on the activation status of the cell (Busse et al. , 1996). 
Therefore, in samples where eosinophil activation is high (generating a hypodense 
population) , the purified eosinophils may represent a sub-population. In addition , the 
bone marrow contains many immature eosinophils which will also have a variable 
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density. Hence, the density of the gradient will have to be carefully optimized to permit 
the maximum recovery of eosinophils. 
The FACS~based purification method possesses certain advantages which include 
ease of sample preparation, reproducible sample purity, the method does not require 
the ligation of a cell-surface marker with an antibody and it can be applied to many 
sources of eosinophils. Furthermore, the procedure may also be used as an 
identification tool rather than a purification method. The alternative approach may be 
used to rapidly screen for differences in cell surface markers on eosinophils. It should 
be noted that lymphocyte, neutrophil and macrophage populations can also be 
analyzed in a single experiment. Although not indicated on the FACS plots, all 
leukocytes can be distinguished from one another. 
The advantages provided by this purification method make it an ideal procedure to 
compare the phenotypes of different leukocyte populations. Firstly, the preferable 
purification methods are based on a negative selection procedure because they do not 
require the ligation of a cell-surface marker with an antibody on the cell under 
selection. This prevents the introduction of artefactual results due to the potential 
activation of intracellular signaling cascades in response to the binding of the antibody 
to a receptor. The FACS-based method avoids this problem as it takes advantage of 
physical properties of each leukocyte population. Furthermore, only one purification 
method is required to isolate eosinophils from the bone marrow, blood and BALF which 
prevents the differences in phenotype being attributable to the isolation methods 
themselves. Importantly, the purification method results in the isolation of viable and 
stimulus-responsive eosinophils suggesting that the stresses imposed by the 
purification method are not harmful to the cells. Collectively, the analysis suggest that 
the purification method will permit an accurate comparison of the different eosinophil 
populations. 
The method was developed to study phenotypic differences within eosinophil 
populations as they migrate from the bone marrow to sites of inflammation. An initial 
screening procedure, called subtractive hybridization, was to be employed to identify 
mRNA transcripts which are differentially expressed in the eosinophil populations. The 
results in the previous Chapter suggest that comparison of bone marrow and BALF 
eosinophils should permit the identification of gene·s involved in the differentiation, 
migration and activation of eosinophils. Due to the high sensitivity of subtractive 
hybridization, intact RNA must be isolated to prevent artefactual results . Unfortunately, 
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initial attempts to isolate total RNA from mouse eosinophils failed. These results might 
have been due to the high concentrations of RNAses in eosinophils. Both EON and 
ECP possess ribonuclease activity (Domachowske et al., 1998a; Domachowske et al., 
1998b). In order to circumvent these problems, multiple modifications to the procedure 
were attempted to optimize the method. While performing a second extraction with the 
one-step solution enhanced the purity and quality of the RNA, all other modifications 
failed to further improve RNA quality. Importantly, total RNA which was isolated from 
eosinophils with the best extraction method did not display the traditional band pattern 
upon gel electrophoresis (28S/18S ration). It is unknown whether the pattern observed 
for total RNA from eosinophils represents the status of RNA in the cell or is due to 
partial degradation of the RNA during the extraction procedure. However, analysis of 
all the collected data suggests that the first proposition might be correct. Firstly, the 
RNA isolated from the total leukocytes present in the bone marrow and BALF display 
the appropriate intensity ratio between the 28S and 18S bands. Thus, very little 
degradation occurs during the isolation of total RNA most likely because the one-step 
solution stabilizes the RNA and inhibits eosinophil RNases. The material near the 
bottom of the gel might be degradation products of total RNA. However, it must occur 
in the cells before lysis. Furthermore, since this band is amplified in the eosinophil 
sample, it may be originating from these cells. It could be the result of cells which are 
actively undergoing apoptosis or cell death. However, viability of cells in all samples 
was always very high. Finally, RT-PCR analysis of GAPDH demonstrated that the 
levels of this gene are equal between bone marrow and BALF eosinophils. Moreover, 
the results were reproducible between different RNA samples which were isolated on 
separate occasions. The data strongly suggests that the total RNA extracted from 
eosinophils represents the conditions within the cell. However, it cannot be excluded 
that degradation of the RNA occurs at various stages of the experimental protocol. 
Preliminary experiments demonstrated that subtractive hybridization might lead to the 
discovery of many genes. By means of semi-quantitative RT-PCR, several cytokines, 
cytokine and chemokine receptors were determined to be differentially expressed 
between the bone marrow and BALF eosinophils . A representative subset of genes 
from each family were initially analyzed. These genes were selected since they play an 
important role in eosinophil biology and/or have been implicated in the pathogenesis of 
allergic airways disease. 
Eosinophils express a number of Th1 and Th2-type cytokines (Woerly et al. , 1999). 
Although allergic diseases arise from a Th2-type immune response , activated 
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eosinophils in BALF induce the expression of cytokines regardless of the class of 
immune response with which they are associated. Hence, not only is the expression of 
IL-4 , IL-5 and IL-13 upregulated in BALF eosinophils but also , IL-12 and IFN-y. The 
significanc·e of the increase in expression of both Th1 and Th2-type cytokines in 
activated eosinophils during a Th2 immune response is unclear. 
IL-5 is involved in the differentiation of eosinophils (Sanderson et al., 1985) and signals 
via the IL-5Ra subunit in complex with a common ~ subunit of the IL-3, IL-5 , GM-CSF 
receptors (D'Andrea and Gonda , 2000). Interestingly, an increase in mRNA levels of 
the IL-5Ra gene was detected in activated eosinophils. This result is unexpected but 
may reflect the importance of IL-5 signaling in priming the eosinophils for chemotaxis 
and activation (Carlson et al., 1993; Fujisawa et al., 1990; Kita et al., 1992; Sehmi et 
a/., 1992; Takafuji et al., 1996; Warringa et al., 1992) along with serving as a survival 
signal (Yamaguchi et al., 1991 ). 
Various chemokine receptors previously reported as expressed on the surface of 
eosinophils were also up-regulated in BALF eosinophils (Jinquan et al., 2000; 
Rothenberg et al. , 1999). Notably, human eosinophils undergo chemotaxis in response 
to MCP, a ligand of CCR-4 (Bochner et al., 1999). However, the authors were unable to 
detect CCR-4 mRNA or protein expression in human eosinophils (Bochner et al., 
1999). In agreement with the human study, Borchers and colleagues (2002) could not 
detect CCR-4 expression in IL-5 Tg mouse eosinophils by RT-PCR. In contrast, we 
found that mouse eosinophils isolated from the bone marrow and BALF of allergic mice 
express CCR-4 mRNA with the transcript up-regulated upon activation of the cell . The 
differences between the two studies may be due to the source of eosinophils and/or 
the primer sets used for RT-PCR. To settle the discrepancy, detection of CCR-4 
transcripts in mouse eosinophils from the different sources should be performed by 
Northern blot. Although eotaxins are believed to strongly contribute to the migration of 
eosinophils into tissue , ligands for CCR-1 , CCR-3 , CCR-4 and C-x-C chemokine 
receptor (CxCR)-3 may also contribute to the process of eosinophil recruitment. 
Emerging evidence has identified IL-13 as a key regulator of allergic airways disease. 
This cytokine modulates several biological funct ions associated with allergic diseases 
including the recruitment of inflammatory cells , mucus hypersecretion and AHR (Grunig 
et al., 1998; Matsukura et al. , 2001 ; Moore et al., 2002 ; Terada et al. , 2000; Venkayya 
et al., 2002 ; Walter et al., 2001 ; Wills-Karp et al., 1998). Both IL-4 and IL-13 initiate 
signaling cascades within a cell by means of a common IL-4Ra chain (Gallard et al. , 
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1996). This receptor component must heterodimerize to form an active receptor. In the 
case of IL-13, two receptor chains regulate IL-13 signaling namely, IL-13Ra 1 and IL-
13Ra2 (Gallard et al., 1996; Kawakami et al., 2001 ). However, recently new evidence 
suggests that IL-13 may signal via additional receptor systems independent of the IL-
4Ra chain (Mattes et al., 2001 ). With regards to eosinophils , IL-13 has been implicated 
in cell survival , chemotaxis and activation of this leukocyte (Dubois et al., 1998; Horie 
et al., 1997b; Luttmann et al., 1996). Due to the emerging importance of I L-13, the 
expression of this cytokine and its receptors in eosinophils was investigated. 
Eosinophils can contribute to the pathogenesis of allergic diseases not only by 
secreting cytotoxic cationic proteins but maybe also by releasing IL-13. The expression 
of IL-13 was highly up-regulated in BALF eosinophils. Since IL-13 induces the 
production of eotaxin in the lung (Hirst et al., 2002; Matsukura et al., 2001 ), eosinophils 
may promote the recruitment of additional eosinophils by releasing this cytokine. In 
addition , eosinophil-derived IL-13 could promote AHR (Grunig et al., 1998; Venkayya 
et al., 2002; Wills-Karp et al., 1998; Yang et al., 2001 ). In agreement with previous 
functional assays (Dubois et al., 1998; Horie et al., 1997b; Luttmann et al., 1996), 
subunits of the IL-13 receptor were constitutively expressed in mouse eosinophils. In 
particular, IL-4Ra and IL-13Ra1 subunits were expressed in bone marrow at a basal 
level, which was increased in activated eosinophils but the IL-13Ra2 subunit was not 
observed in either population. Further studying the role of IL-13 in the regulation of 
eosinophils may highlight novel roles of this cytokine in eosinophil biology. 
Only one gene, namely MBP, displayed a higher expression level in eosinophils from 
the bone marrow compared to eosinophils present in the BALF, which is consistent 
with previous results using human eosinophils (Gruart et al., 1992). MBP is one of the 
cytotoxic cationic proteins which are stored in secondary granules. Potentially , the 
other members of this protein family including EPO, ECP and EON may also display a 
similar expression profile as reported for their human counterparts (Gruart et al., 1992). 
The formation of secondary granules occurs primarily in progenitors and is complete in 
mature eosinophils (Popken-Harris et al. , 1998). Therefore, the expression of these 
genes would be expected to be highest in the bone marrow fraction as indicated by the 
results for MBP. However, this prediction cannot be made about all proteins involved in 
similar structures . Proteins associated with lipid bodies should be most highly 
expressed in BALF eosinophils since the number of lipid bodies increases upon 
activation of eosinophils (Bozza et al. , 1998). 
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The gene expression profile of MBP also provides additional information about the 
quality of the RNA. Degradation of the total RNA isolated from bone marrow 
eosinophils cannot explain the previous results obtained for the expression of 
cytokines, cytokine and chemokine receptors because other genes, in particular MBP, 
show a higher level of expression in the bone marrow sample . If the RNA was 
degraded, these differences would be lost or BALF eosinophils would display a higher 
gene expression. Collectively, the data provide strong support to pursue the generation 
and characterization of cDNA libraries by subtractive hybridization. The screening 
procedure may reveal the presence of a large number of differentially regulated 
transcripts and potentially , the discovery of novel genes involved in modulating 
eosinophil differentiation , migration and activation. 
In conclusion , these investigations have provided a platform to further study eosinophil 
biology and compare the phenotype of various eosinophil populations. A method based 
on the light polarization properties of cells allows for the purification of viable and 
stimulus-responsive eosinophils from the bone marrow, peripheral blood and BALF of 
allergic mice. Furthermore, the extraction of total RNA from eosinophils has been 
optimized leading to the discovery of several differentially expressed genes using RT-
PCR by bone marrow and BALF eosinophils. A complete characterization of the three 
eosinophil populations may provide additional insight into the molecular mechanisms 
regulating eosinophil differentiation , migration and activation . 
General discussion and conclusions 
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4.1 DIFFERENTIAL REGULATION OF EOSINOPHIL DEGRANULATION 
BETWEEN SPECIES 
During the last 5 years, a debate has emerged about the relevance of mouse models 
of allergic · airways disease as experimental systems to study human disease 
processes. In particular, eosinophil degranulation, a key feature of the asthmatic lung, 
had not been demonstrated to occur in the lungs of allergic mice. This thesis has 
provided another perspective on this debate. While the data is in agreement with the 
previous studies depicting a low number or the absence of activated eosinophils in the 
lung submucosa (Malm-Erjefalt et al., 2001; Stelts et al., 1998), eosinophils are highly 
activated in the airway lumen. Furthermore, the proteins released into the airway cavity 
can promote pathogenesis of disease as they diffuse through the tissue to reach 
cellular targets. This observation is very interesting because Erjefalt and Persson 
(2000) have proposed that the infiltration by eosinophils into the airway lumen is a 
unidirectional pathway for the resolution of the tissue eosinophilia. However, this study 
in addition to several others (MacKenzie et al., 2001; Shen et al. , 2003; Shi et al., 
2000), now suggest that while these migratory processes may serve as a mechanism 
for eosinophil clearance, they also permit the eosinophil to have a significant impact on 
disease. 
One issue which remains unresolved, and could be the subject of future investigations, 
i~ the reasons for the different eosinophil phenotypes observed in the allergic lungs of 
humans and mice. Two plausible explanations can be hypothesized: 1) the micro-
environment in the allergic lungs of humans and mice is significantly different and 2) 
eosinophil degranulation is differentially regulated between species. It would be difficult 
to address the first issue because our knowledge of the events leading to the 
pathogenesis of allergic diseases is yet to be fully defined. Novel genes which may 
encode chemokines and cytokines are being discovered on a regular basis. These 
classes of molecules may play an important role in mediating Th2 immunopathological 
processes, thus contributing to the development of pathophysiological features of 
allergic diseases. However, new high-throughput technologies may assist in 
determining whether differences in the micro-environment of allergic lungs exist 
between species . For example , DNA micro-chip analysis and/or application of 
proteomics (20 gels/ mass spectrometry) to this question would allow to identify the 
mRNA transcripts and the proteins which are differentially expressed in the allergic 
lung of mice and humans. 
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Although a more accurate reproduction of the micro-environment observed in the 
asthmatic lung would be beneficial , it may not necessarily lead to eosinophil 
degranulation in the lung submucosa of mice. The mechanisms regulating eosinophil 
activation -may be very distinct between species. A previous study revealed that 
important differences in the response to exogenous stimuli exist between human and 
mouse eosinophils (Malm-Erjefalt et al., 2001) . However, the nature of these 
differences was never characterized . This thesis extends our knowledge with regard to 
these differences. Although the kinetics of adhesion and degranulation were 
conserved , mouse eosinophils required higher concentrations of exogenous stimuli to 
trigger cellular activation than human cells (Horie and Kita , 1994; Reimert et al. , 1998). 
This difference may contribute to the low level of eosinophil activation observed in the 
allergic lung of mice. 
This basic difference in eosinophil activation may only be one of several differences. 
Another important question which remains unresolved regards the identification of 
physiological stimuli , which induce eosinophil degranulation. Do mouse eosinophils 
respond to the same stimuli as human cells? From the data in this thesis , we can 
conclude that at least some elements are preserved because mouse eosinophils also 
secreted MBP upon stimulation with antigen (OVA) . OVA was selected as a possible 
candidate for inducing activation because antigen affects human eosinophil activation 
(Kaneko et al., 1995b; Tomassini et al., 1991 ), mouse eosinophils interact with OVA 
and present this antigen through MHC-11 (MacKenzie et al. , 2001 ; Shi et al. , 2000) and 
OVA is a prominent molecule in the airway lumen during allergic airways inflammation . 
Interestingly, signals from T-cells in association with cognate antigen also appear to 
control eosinophil degranulation during parasitic infections in mice (Shinkai et al., 
2002) . The results suggest that the reproduction of the conditions present in the airway 
lumen may enable the identification of other physiological stimuli activating eosinophil 
degranulation. Methods exist for the isolation of tracheal epithelial cells (Kumar et al. , 
1997) . By co-culturing these cells in conjunction with eosinophils in a media generated 
from activated Th2 lymphocytes, the effect of a wide range of molecules could be 
analyzed at once. Another approach to the problem would be to compare the stimuli 
present in the lung submucosa during allerg ic inflammation with those present in the 
airway lumen , since eosinophil degranulation does occur in this latter compartment. 
While a tissue eosinophilia is associated with allergic diseases, the physiological role of 
eosinophils is believed to reside in host defense against parasite infections (Behm and 
Ovington , 2000 ; Meeusen and Bal ic, 2000). Comparing the response of eosinophils to 
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signals emitted during a parasitic infection and allergic disorders could provide another 
alternative method to further study mouse eosinophil activation. 
Unfortunately , the current methods developed to study eosinophil activation in vitro 
have several limitations. The method reported in this thesis provides only a semi-
quantitative analysis. Thus, the greatest challenge is to develop a better assay which 
would allow quantification of the level of secreted granule proteins. This methodology 
would increase the sensitivity of the degranulation assay and allow the detection of 
lower levels of degranulation. The immunodot blot is very insensitive and will only 
permit the detection of large quantities of MBP. Adapting the EPO detection method to 
the degranulation assay was attempted. However, it was discovered that the enzyme 
binds to the matrix used to coat the well and is unstable at 37°C (data not shown). The 
need for a sensitive assay is highlighted by the in vitro data collected from human 
eosinophils. Eosinophil degranulation does not appear to be a primary response to 
most stimuli as long periods of time (4 hours) are required to achieve full activation and 
only a small fraction (5-20°/o) of the total amount of protein available is secreted into the 
environment (Abu-Ghazaleh et al., 1989; Fujisawa et al., 1990; Horie et al., 1996; Horie 
and Kita, 1994; Kaneko et al., 1995b; Kroegel et al., 1989; Takafuji et al., 1994). 
4.2 EOSINOPHIL PURIFICATION FROM BONE MARROW, BLOOD AND 
BALF OF ALLERGIC MICE BY FACS 
The final contribution of this thesis to understanding eosinophil biology is the 
development of a method to purify eosinophils from the bone marrow, blood and BALF 
of allergic mice. To date, most methods only permit the isolation of mouse eosinophils 
from one compartment (Rothenberg et al., 1995; Shinagawa and Anderson, 2000; 
Teixeira et al., 1997). This limitation arises from the inability of the purification strategy 
to differentiate the granulocytes from one another. In order to purify eosinophils , the 
light polarization properties in conjunction with the SSC of cells were selected as 
criteria to separate all leukocyte populations including the granulocytes. This FACS-
based method overcomes the primary limitation of other purification strategies and 
permits to differentiate neutrophils and eosinophils . This new method will permit 
comparative studies using functional assays , DNA micro-chip analysis and proteomics 
to identify phenotypic differences between each eosinophil population . In the long term , 
these future investigations could reveal key regulators of eosinophil differentiation , 
migration and activation which may serve as drug targets for novel therapeutics of 
allergic diseases. 
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A major benefit of this purification method is that a single procedure is utilized to isolate 
eosinophils from each compartment. Under these circumstances , all cells would be 
subjected to similar stress during purification. Furthermore, the ligation of an antibody 
to an antigen present at the surface of eosinophils is not required. This prevents the 
non-specific activation of receptor systems, which could alter the phenotype of the 
cells . Therefore, this procedure , most probably, results in eosinophil populations 
displaying gene expression profiles representative of the outcome of the multitude of 
signals present in vivo. 
The method also permits the isolation of viable and stimulus-responsive cells. In this 
thesis, only PMA was utilized as a control to assess this feature of the eosinophil 
populations. In the future, a more detailed analysis of the response of eosinophils 
isolated from the various compartments to physiological stimuli may highlight significant 
phenotypic differences. 
Unfortunately , the method has certain limitations. The most important one is the low 
yield especially in samples containing high neutrophil numbers. Although eosinophils 
polarize light significantly more than neutrophils, the profile on FSC vs. SSC and light 
polarization plots slightly overlap. Therefore, in order to obtain a high sample purity, it is 
necessary to apply very narrow gates which exclude all neutrophils and allow for the 
selection of eosinophils . A significant disadvantage may arise from this process as the 
purified population may not represent the diverse phenotypes of eosinophils in the 
original sample but may be a sub-population. However, the yield of eosinophils can be 
increased but to the detriment of the purity. 
Future investigations may be pursued to improve the eosinophil purification strategy by 
adding an additional selection criteria which would further distinguish the neutrophil 
and eosinophil populations. Certainly , a positive selection marker such as the 
expression of CD49d , CCR-3 or IL-5Ra on eosinophils would have improved the yield 
and potentially , the purity. On the other hand , the ligation of the receptor with an 
antibody may change the overall phenotype of the eosinophil. Hence, the best option to 
avoid this manipulation of the ce lls is a negative selection marker for eosinophils . 
Human neutrophils are separated from eosinophils on the basis of differential 
expression of CD16 (Gopinath and Nutman , 1997; Hansel et al., 1991 b). Unfortunately, 
this procedure cannot be adapted for the isolation of mouse eosinoph ils because of 
two major limitations: 1) mouse eosinophils constitutively express CD16 (de Andres et 
al., 1994) and 2) the only antibody available which detects mouse CD16 , also detects 
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CD32 which is highly expressed on mouse eosinophils (de Andres et al., 1994; 
Serrander et al., 2000) . By developing an antibody, which recognizes an epitope 
present specifically on neutrophils , would significantly enhance the purification 
procedure. · Finally , a density gradient may be suitable to separate both granulocyte 
populations (Borchers et al., 2002 ; Shen et al. , 2003). However, this procedure may 
lead to the preferential purification of an eosinophil population , especially in samples 
where eosinophil activation is very high, because activated eosinophils are hypodense. 
A comparison by semi-quantitative RT-PCR of the expression of a selection of genes 
involved in the pathogenesis of allergic diseases revealed that granule proteins , 
cytokines and their receptors and chemokine receptors are differentially expressed 
between bone marrow and BALF eosinophils. Notably, IL-13 is highly expressed in 
BALF eosinophils. Furthermore, the IL-4Ra and IL-13Ra 1 transcripts are up-regulated 
in activated eosinophils. Since IL-13 has been recently shown to play an instrumental 
role in the pathogenesis of allergic airways disease (Grunig et al. , 1998; Mattes et al., 
2001; Walter et al., 2001; Wills-Karp et al. , 1998), eosinophils may respond to IL-13 
signaling as well as transmit IL-13 -based signals to affect disease processes. Based 
on these limited results, future research should focus on screening the genome for 
differentially regulated genes in eosinophil populations using DNA micro-chip 
technology or subtractive cloning. These experiments may highlight novel mechanisms 
utilized by eosinophils to affect the pathogenesis of allergic diseases. 
4.3 CONCLUDING REMARKS 
This thesis has provided new insights into the role of eosinophils in mouse models of 
allergic pulmonary inflammation and new methods to further investigate the 
mechanisms regulating eosinophil activation . Additional research which aims at 
understanding the molecular mechanisms of mouse eosinophil degranulation in 
collaboration with comparative studies of the micro-environment in the allergic lungs of 
humans and mice will permit the development of improved mouse models of allergic 
airways disease. These models may be helpful in the development of novel 
therapeutics for allergic diseases. 
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